Dr  Dion  Forstner   Postal  Address:-­‐   Contact  Numbers:  MBBS  (Hons),  FRANZCR   Cancer  Services   Phone:    (02)  8738-­‐9805  Director  of  Radiation  Oncology   Locked  Bag  7103   Fax:    (02)  8738-­‐9819      LIVERPOOL  BC  NSW  1871  

  15 May 2015

Ms Annamarie D’Souza Manager Research and Ethics Office South Western Sydney Local Health District Locked Bag 7103 Liverpool BC NSW 1871

Dear Ms D’Souza

Re Academic Unit Expression of Interest (EOI)

Thankyou for the opportunity to apply for a SWSLHD academic unit grant. Please find attached the Liverpool Hospital and Campbelltown Hospital Department of Radiation Oncology’s EOI for the academic unit grant with the following documents included;

• EOI • Radiation Oncology research strategic plan 2015-2020 • Appendix • Proposed budget • Radiation Therapy Research Coordinator draft position description • CVs of academic staff

I would be very happy to discuss any matters that arise during the consideration of this EOI. Yours sincerely

Dr Dion Forstner Director of Radiation Oncology Liverpool & Campbelltown Hospitals, South Western Sydney Local Health District

SWSLHD Academic Unit Expression of Interest- due 15th May

A submission from the Department of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centres

This document has been prepared by the Radiation Oncology Research Executive Committee. For any questions please contact A/Prof Lois Holloway (Chair of the Radiation Oncology Research Executive Committee) or Dr Dion Forstner (Director of Radiation Oncology).

Table of Contents

2.1 A unit of SWSLHD .......................................................................................................................... 2

2.2 Academic appointments ............................................................................................................... 3

2.3 Research Program ......................................................................................................................... 4

2.4 Research Strategy ......................................................................................................................... 5

2.5 Research Track Record .................................................................................................................. 6

2.6 Teaching and Mentorship ............................................................................................................. 7

2.7 Supporting Documents ................................................................................................................. 9

1

2.1 A unit of SWSLHD • The Department of Radiation Oncology functions as a single unit and provides all the

radiation oncology clinical services within SWSLHD.

• There are two treatment centres – one based at Liverpool Hospital and the other based at

Campbelltown Hospital. Outpatient clinics are held in Bowral and at Bankstown Hospital.

• The unit is multi-professional being made up of radiation oncologists, radiation oncology

medical physicists, radiation therapists, nurses, administration staff, and allied health staff.

• The Department has over the last 13 years provided a networked service between Liverpool

& Campbelltown Hospitals with staff, equipment and other resources shared. Although staff

are appointed to one facility, the majority work across the two facilities.

• The Department is one of the leading examples of a highly developed and successful service

networked across SWSLHD.

• The department developed its first formal research strategic plan in 2010 for the period

2010 -2015. A new strategic plan 2015-2020 has been developed and is included in this

submission.

• The department has state of the art radiation therapy equipment – both research and

clinical with the first radiation oncology dedicated MRI scanner in the country, Tomotherapy

unit (delivers radiation therapy much like a CT scanner works), has two new linear

accelerators at its Campbelltown site, and has significant research infrastructure supported

both externally and internally.

2

2.2 Academic appointments

Staff Member Discipline Academic Appointment Level

University

Professor Michael Barton

Radiation Oncology Level E UNSW

Professor Geoff Delaney

Radiation Oncology Level E UNSW, UWS

Associate Professor Shalini Vinod

Radiation Oncology Level D UNSW, UWS

Associate Professor Gary Liney

Medical Physics Level D UNSW, University of Wollongong

Associate Professor Lois Holloway

Medical Physics Level D UNSW, University of Wollongong, University of Sydney

Dr Dion Forstner Radiation Oncology Level C UNSW

Dr Mark Sidhom Radiation Oncology Level C UNSW

Dr Miriam Boxer Radiation Oncology Level C UNSW

Dr Eng-Siew Koh Radiation Oncology Level C UNSW

Dr Mark Lee Radiation Oncology Level C UNSW

Gary Goozee Medical Physics Level C UNSW

3

2.3 Research Program

Research is a major focus for Liverpool & Macarthur Cancer Therapy Centres, as is witnessed by the

large number of ongoing research projects. In the past 5 years, there have been over 80 research

projects that were initiated and led by local investigators. A Significant majority of the research is of

a collaborative nature that has been established across multidisciplinary groups. There has been a

significant increase in co-operative research between radiation oncology, radiation therapy and

medical physics. There is collaborative research with other Liverpool Hospital and SWSLHD

Departments – including the Departments of Radiology, Nuclear Medicine, Cardiology and several of

the surgical units (colorectal, breast, and head and neck). There is also significant collaborative

research being conducted with external bodies nationally and internationally such as universities

and CSIRO. These research projects are not limited to senior staff members. Junior and new staff

members are encouraged to undertake research or be involved in ongoing projects and are

mentored to develop skills in this area.

A key research focus demonstrating multidisciplinary research are a series of research projects

currently investigating the use of magnetic resonance imaging (MRI) for radiotherapy. These projects

rely on input from radiation oncologists, radiation therapists and medical physicists for success and

also provide unique research opportunities for each of these professional groups. As the first

department in Australia with its own dedicated MRI simulator we are ensuring a high level of

multidisciplinary collaboration to take full advantage of this opportunity, with the end benefit

improved treatment for our patients.

4

2.4 Research Strategy

The radiation oncology research strategic is detailed in our attached research strategic plan. In brief our goal is to further develop our research output for the benefit of our patients in key research areas. Our specific research objectives for 2015-2020 are detailed in the table below together with the alignment of these goals with the SWSLHD research aims. Radiation Oncology Strategic Plan Objectives Alignment with SWSLHD research aims

1. Achieve high quality research This objective aligns with the SWSLHD aim to Strengthen the quality and quantity of research in the SWSLHD.

2. Further develop our research governance structure

This objective aligns with the SWSLHD aim to Develop governance arrangements which ensure accountability and responsibility for research conducted according to ethical principles, scientific, regulatory and professional standards and the principles of risk management.

3. Provide high quality research training and mentoring

This objective aligns with the SWSLHD aim to Encourage new researchers, including junior staff, and, sustain the commitment to research of SWSLHD personnel in management, support and research roles.

4. Attract and maintain high quality staff and students

This objective aligns with the SWSLHD aim to Strengthen the quality and quantity of research in the SWSLHD.

5. Attract external funding to achieve on-going research

This objective aligns with the SWSLHD aim to Identify resourcing required to implement the strategies in the Plan and potential sources of funding.

6.Facilitate and strengthen research collaborations

This objective aligns with the SWSLHD aim to Support and further develop the capacity for research across the SWSLHD.

7. Develop recognised world leading status in a limited number of chosen areas

This objective aligns with the SWSLHD aim to Enhance the profile of current research in the SWSLHD.

8. Undertake high quality clinical trials This objective aligns with the SWSLHD aim to Strengthen the quality and quantity of research in the SWSLHD

9. Consumer Involvement in research projects This objective aligns with the SWSLHD aim to Ensure structures support creativity and lead to research which improves health and health service provision.

10. Translation of research developments into clinical practice

This objective aligns with the SWSLHD aim to Ensure structures support creativity and lead to research which improves health and health service provision.

5

2.5 Research Track Record

Category One grants

Over the last 5 years our department has received funding from 23 category one grants totalling

over $20million. Details of these grants are given in the appendix.

Peer reviewed publications

Over the last 5 years our department has published 134 research articles and 8 book sections.

Details of these publications are given in the appendix

Clinical trials

Over the past 5 years our department has been involved with over 20 radiation oncology clinical

trials. Details of these trials are given in the appendix.

National and International invited presentations and awards

Over the past 5 years staff in our department have been invited to give over 70 invited presentations

and have received 19 awards. Of importance these presentation invitations and awards have been

received by 19 individual staff members rather than a limited one or two.

6

2.6 Teaching and Mentorship

Teaching and Mentorship

Craft Group

Radiation Oncology Medical Physics Radiation Therapy Undergraduate teaching

All radiation oncologists contribute to undergraduate teaching at UNSW or UWS. Dr Karen Wong is the radiation oncology coordinator for phase 2 and Dr Dion Forstner for phase 3. Assoc Prof Vinod, Dr Koh, Dr Mark Lee and Dr Forstner have all supervised ILP students. Several radiation oncologists examine at an undergraduate level.

Dr Philip Vial and A/Prof Lois Holloway have contributed to undergraduate physics research training at the University of Wollongong and the University of Sydney.

All qualified radiation therapists (Level 2 and above) contribute to undergraduate teaching at the department during clinical placements from USYD (until 2013) and University of Newcastle (current). Ms Melanie Rennie and Mrs Carol Wilder are Radiation Therapist Educators responsible for overseeing undergraduate students.

Post graduate teaching

All radiation oncologists are term supervisors for registrar advanced training undertaken through the Royal Australian and New Zealand College of Radiologists (RANZCR). Dr Miriam Boxer and Dr Mei Ling Yap are Directors of Training for RANZCR training. Dr Dion Forstner was the southern NSW radiation oncology training network director 2012-13. Prof Geoff Delaney is on the faculty of ACORD.

A/Prof Lois Holloway and Dr Philip Vial were involved in establishing the radiobiology and dosimetry Masters courses at the University of Sydney and A/Prof Gary Liney has been involved in teaching in the imaging course at the University of Sydney. A/Profs Holloway and Liney and Dr Vial have all also been involved in teaching for the University of Wollongong Medical physics Masters program

All Level 3 and Level 4 radiation therapists are responsible for supervising intern radiation therapists (Level 1) undertaken through the Australian Institute of Radiography (AIR). Ms Melanie Rennie and Mrs Carol Wilder are Radiation Therapist Educators responsible for overseeing interns.

Continuing Professional Education

Dr Dion Forstner as Dean of the Faculty of Radiation Oncology RANZCR overseas the

Dr Gary Goozee is a ACPSEM radiotherapy certification examiner. Dr Philip Vial, A/Prof

The current CPD programs for radiation therapists include weekly in-service

7

work of the Chief Censor, and sits on the Education and Training Committee which is responsible for all radiation oncology advanced training. In his college role he also overseas the work of the post fellowship education committee and is currently very actively involved in developing a revalidation tool to be implemented college wide for all fellows in Australia and New Zealand.

Lois Holloway and Mr Michael Jameson were involved in the development of the current medical physics TEAP training scheme. A/Prof Gary Liney is involved in teaching for the European Society of Therapeutic Radiation Oncology advanced imaging course. Drs Philip Vial and Sankar Arumugam and Ms Tania Erven are all members of the NSW branch of the ACPESM and involved in organising NSW scientific meetings. A/Prof Holloway and Dr Vial have had and continue to have involvement in coordinating both national and international medical physics meetings.

program with topics of interest determined by RT staff and management. All staff are given time to ensure their mandatory education requirements are up to date. All RT staff are welcome to express interest in attending conferences and meetings of interest with a strong focus on presenting work developed within the department.

Higher Degree Student Completion

- Karen Wong (PhD) - Stephen Thompson (PhD) - Gabriel Gabriel (PhD) - Susannah Jacob (PhD)

- Sam Blake (PhD) -Alexandra Quinn (PhD) -Sankar Arumugam (PhD) -Phil Vial (PhD) -Jarrad Begg (MSc) -Marius Hoppe (MSc) -Omemh Bawazer (MSc) -Michael Hrynevych (MSc) -Thahabah Alharthi (MSc) -Ming Teo (MSc) -Jin Jaijie (MSc) -Svenja Ipsen (MSc) -Yvette Griffiths (MSc) -Madeleine Tyler (MSc) -Tania Tehovnic (MSc)

-Daniel Moretti (MBA: Health Management) -Adrianna Scotti (Masters in Health Service Management) -Sandie Watt (Masters in Health Science) -Ewa Juresic (Masters in Magnetic Resonance Imaging) -Andrew Wallis (Masters in Clinical Leadership and Supervision) -Robba Rai (Masters in Health Science) -Giselle Condos (MBA: Health Management) -Vikneswary Batumalai (Masters in Health Science)

8

-Shivani Kumar (Masters in Public Health)

Current Higher Degree students

-Tim Hanna (PhD) -Jesmin Shafiq (PhD) -Viet Do (PhD) -Jacqueline Veera (PhD) -Myo Min (PhD) -Trang Pham (PhD)

-Michael Jameson (PhD) -Shrikant Deshpande (PhD) -Tony Young (PhD) -Amy Walker (PhD) -Brendan Whelan (PhD) -Lauren Bell (PhD) -Jeff Barber (PhD) -Sarah Algnaghy (PhD) -Thahabah Alharthi (PhD) -Trent Causer (PhD) -Nadeeja Wijesekera (PhD) -Dale Roach (MSc) -Tariro Ndoro (MSc)

-Shivani Kumar (PhD) -Vikneswary Batumalai (PhD) -Rohan Gray (Masters in Health Industry Management) -Mark Udovitch (MBA: Health Management) -Kirrily Cloak (MBA: Health Service Management)

2.7 Supporting Documents Attached are:

1. An appendix detailing both the publication list for the last 5 years and grants, clinical trial involvement, invited presentations and awards for the last 5 years.

2. CVs for academic appointments listed in 2.2 3. The department research strategic report for 2015-2020 4. A Proposed Budget & Job description

9

1

Department of Radiation Oncology South Western Sydney Local Health District

Research Strategic Plan 2015-2020

This document has been formulated by the radiation oncology research executive committee; Lois Holloway (chair - medical physics), Dion Forstner (radiation oncology), Vikneswary Batumalai (radiation therapy), Philip Vial (medical physics), Shivani Kumar (radiation therapy), Lynette Cassapi (radiation therapy), Gary Goozee (medical physics), Mark Lee (radiation oncology), Melissa Grand (clinical trials). The stakeholders in this research strategic plan are the staff, current and future patients of the radiation oncology department at Liverpool and Macarthur Cancer Therapy Centres and our research collaborators. This document was prepared to update our previous research strategic plan (2011-2015) providing current research priorities for assessment of projects undertaken in the department, long term goals for staff and department development and to provide focus for the research executive committee such that short term goals can be established.

2

Table of contents 1. Our Vision ...................................................................................................... 3

2. Our Department ............................................................................................. 4

2.1 Our research groups and our key areas of research interest ................... 5

2.2 Our Research Staff .................................................................................. 7

2.3 Research structure ...................................................................................... 9

2.4 Research Mentoring for Individuals .................................................................. 12

2.5 Research support for strategic research areas.......................................... 14

2.6 Our collaborators ....................................................................................... 14

3. Our Objectives ................................................................................................ 16

3.1 Achievements and Challenges from our previous strategic plan (2011-2015) …………………………………………………………………………………16

3.2 Key objectives to achieve our vision for 2015-2020 ...................................... 19

4. Priority research areas 2015-2020 ............................................................... 23

3

1. Our Vision To conduct high quality research in radiotherapy, driving change in clinical practice at a departmental, national, and international level. Our research is focused on improving outcomes and patient care through technology development, clinical investigations and health services research, and in line with SWSLHD research aims.

4

2. Our Department Radiation Oncology, also commonly termed radiotherapy, refers to the use of ionising radiation to treat cancer (or occasionally non-malignant disease). As demonstrated by our department according to the best available clinical evidence 48.3% of cancer patients should receive radiation therapy at some point in their cancer journey. Radiation Oncology is a clinical and technology focussed medical specialty made up of a multidisciplinary team whose aim is to achieve high quality cancer care for our patients. This team consists of radiation oncologists (the doctors responsible for overall treatment and prescription), medical physicists and engineers (the scientists responsible for safe and accurate delivery of the treatment), radiation therapists (the allied health professionals responsible for planning and delivering individual treatments), other allied health and nurses (responsible for patient care). The challenge of successful radiation oncology treatments is to deliver high radiation doses to the cancer while avoiding normal tissues. The ability to achieve this is being constantly improved through improvements in technology achieved through research. Ensuring our patients benefit from these improvements requires an ongoing implementation program of new technologies. The radiation oncology department at Liverpool Cancer Therapy Centre was established in 1995, with a satellite centre, Macarthur Cancer Therapy Centre, established at Campbelltown Hospital in 2003. Our department is based within the South West Sydney Local Health District (SWSLHD). From the initiation of both departments there has been a clear vision from the leadership team to undertake high quality research for the benefit of our patients. The goal of this strategic plan is to support the achievement of this vision in the most effective manner. The Liverpool and Macarthur Cancer Therapy Centres exist as a two-site service in the south west of Sydney, currently seeing over 2200 new patients per year. Our service also includes outreach clinics held at Bowral and Bankstown. The department is the largest academic department in NSW. It currently comprises six linear accelerators including a Tomotherapy unit, one of the newest radiation treatment technologies in the world, one orthovoltage unit and one high dose rate (HDR) brachytherapy unit for clinical use. A further accelerator will be installed at Liverpool in coming years (time frame unknown at the time of writing). We also have two CT scanners and the first radiation oncology dedicated MRI scanner in Australia. There are currently 13 radiation oncologists, 65 radiation therapists and 15 radiation oncology medical physicists. Our department has a very strong research link with the Ingham Institute through key research groups based at the Ingham Institute, joint research programs and many research staff primarily employed through either the hospital or Ingham but with honorary positions and roles of responsibility at the other organisation.

5

Over the last 5 years the department has published over 130 journal papers and received over $20 million in research funding.

2.1 Our research groups and our key areas of research interest

Our department has many well established areas of research interest and expertise. This includes two major research programs initiated within our department, but now conducted within the Ingham Institute with continued involvement, collaboration and support from our department. The Collaboration for Cancer Outcomes Research and Evaluation (CCORE) focusing on health services research is an arm of the Liverpool and Macarthur Cancer Therapy Centres. It was founded by the Radiation Oncology Department in 1999 to improve the outcome of cancer treatment by the better use of existing knowledge. It is led by Professor Michael Barton and the collaboration has particular expertise in radiotherapy but broad interests in all areas of cancer health services research. CCORE has a wide range of activities that extend from the individual cancer patient to the organisation of cancer services at a State or National level and with significant impact on international approaches. Some of the modelling used throughout the world for radiotherapy facility planning is as a result of the work of CCORE. The modelling has now been used by international groups such as The International Atomic Energy Agency (IAEA), the European Society of Therapeutic Radiation Oncology (ESTRO), the Global Taskforce for the use of Radiotherapy for Cancer Control (GTFRCC) and various Australian state governments including NSW and Victoria. Over the last 5 years CCORE has received over $16 million in research funding The Australian MRI-linac program is being undertaken at the Ingham Institute. This program is developing one of only 3 MRI-linac systems being considered internationally which will enable high quality MR imaging in real time during radiotherapy treatment with the potential to dramatically change radiotherapy outcomes. This is a $20 million dollar research program including funding from an NHMRC program grant, the Australian Cancer Research Fund and the Health and Hospitals infrastructure program as well as local support. This program is being led by Prof Paul Keall from the University of Sydney, Prof Michael Barton (UNSW and Ingham Institute) and Prof Stuart Crozier from the University of Queensland. This program involves researchers from the Universities of Sydney, Wollongong, Newcastle, New South Wales, Western Sydney, Queensland and Stanford University, USA. This work is coordinated through a program steering committee containing a number of contributors from our department as well as other collaborators. Research into the use of MRI for radiotherapy has been a major focus for our department over recent years and in particular since the installation of a dedicated radiation oncology MRI scanner in August 2013. This research work

6

includes physics investigations such as accounting for and adapting MRI sequences for radiation oncology, particularly treatment planning use and clinical investigations investigating correlation between MRI information and clinical outcome, considering both tumour response and normal tissue side effects and the potential for individual radiation treatment adaptation based on physiological information available from MRI. This research work has facilitated joint research projects with both the departments of radiology and cardiology at Liverpool hospital as well as a number of national and international institutions. Research undertaken in this area is coordinated through the MRI sim steering committee and the physics research meetings. Research often focused around clinical implementation of novel techniques and approaches is also undertaken in our clinical priority areas. Over recent years this work has included the assessment of the most appropriate radiotherapy techniques for head and neck radiotherapy, the impact of a 6 degrees of freedom radiotherapy couch and the implementation of an extended field of view CT algorithm. Clinical priority areas are determined by the clinical priority document available from the director of radiation oncology. This work is managed by radiotherapy site interest groups which include radiation oncologists, medical physicists and radiation therapists with a particular interest in a given clinical area (e.g. lung, prostate) or by an implementation committee established to manage the implementation of a particular novel technique. Clinical trials provide clinical evidence for treatment changes with the potential to benefit our patients. Level 1 clinical trials provide the highest level of medical evidence and in many instances are essential prior to practice change. Conducting both local investigator-initiated studies and support for national and international collaborative trials, including collaborative groups such as the Trans Tasman Radiation Oncology Group (TROG), where we are a participating site has been challenging over previous years. However this is noted as a key component of an active research department and a radiation oncology clinical trials group has recently been established to provide support for both department initiated and externally initiated clinical trials over the coming years. Clinical trials are managed by both the relevant clinical site groups and the radiation oncology clinical trials group. Our staff are members of all of the national clinical trials groups (such as the Trans-Tasman Radiation Oncology Group, the Australian and New Zealand Breast Cancer Study Group, the Faculty of Radiation Oncology Genitourinary group) and some international groups such as the European Society of Therapeutic Radiation Oncology, the International Breast Cancer Study Group and others. Cancer Survivorship research spanning psycho-social intervention studies, incorporation of e-health technology to aid self-management, examining exercise interventions in survivor populations, as well as identifying novel imaging and clinical correlates of cancer treatment-related toxicity. Part of this work is currently supported through a CI NSW translational centre research grant. This

7

research is managed by Professor Afaf Girgis, Dr Eng-Siew Koh and Professor Geoff Delaney but has significant input from a variety of clinical and research teams and has collaborations with the Illawarra and Shoalhaven Local Health District, the University of Wollongong and the University of Western Sydney. Research into the significance of and methods to account for radiotherapy uncertainties, such as tumour motion and patient positioning during therapy, is a focus of the medical physics research group. This work includes uncertainties in delineating the tumour and normal tissue volumes which define the position of radiotherapy treatment and uncertainties in radiotherapy delivery technology and associated detector systems. These uncertainties will become of increasing importance with future improvements in radiotherapy such as the MRI-linac. This work has been supported by a NSW Cancer Council grant and is managed by the physics research group A recent addition to our research interests includes data mining for the purpose of providing additional evidence for clinicians and patients when making treatment decisions. This work has been established through collaboration with the University of Sydney, MAASTRO clinic, The Netherlands and Illawarra and Shoalhaven cancer therapy centres and has now resulted in a statewide network with plans to expand this to a national network. Using a novel mathematical approach the large amounts of electronic patient data collected for all patient treatments can be modelled in a privacy preserving system such that data does not leave the individual hospital but such that all datasets can be used to develop and overarching outcome and treatment model. This work has received research funding from a NSW Health bioinformatics ‘proof of principal’ grant and is managed by the physics research group and a collaboration of involved institutions. Imaging for radiotherapy purposes including cone beam CT and PET is also a key research interest. There are a number of projects where our department is collaborating with the nuclear medicine department including joint supervision of research students.

Radiation dosimetry one of the key mechanisms for ensuring safe radiotherapy delivery continues to be research focus for our department. This work includes the development of a novel electronic portal imaging device enabling dual imaging and dose verification as well as the investigation into novel detector systems in collaboration with the University of Wollongong. This work has been supported by a cancer council NSW project grant and a Cancer institute NSW infrastructure grant and is managed by the physics research group.

2.2 Our Research Staff

As mentioned above the radiation oncology is a multi-disciplinary service with departments of radiation oncology, radiation therapy, medical physics, allied

8

health and cancer nursing. The department has staff with affiliations with several universities including The University of New South Wales, The University of Western Sydney, The University of Wollongong and the University of Sydney. In addition we have collaborative research links with a number of other institutions and research groups as listed in section 2.6. A large number of staff in our department are involved in research activities, both those employed primarily in a clinical capacity as well as positions primarily devoted to research. Liverpool Hospital funded research positions (using recurrent funding or funding from private practice trust funds) include:

1.5 FTE research medical physicists

2.0 FTE research radiation therapists

0.5 FTE MRI technologist.

3.0 FTE radiation oncology research fellows

2.0 FTE radiation oncology clinical trials staff

Within the CCORE group there are 1.4 FTE health service researchers

In addition to these hospital funded positions the following positions have been established jointly with the Ingham Institute and other collaborating institutions (often through competitive grant funding) and are based within our research groups:

A Chair in Radiation Oncology at Liverpool Hospital (Professor Michael Barton) is funded by The Cancer Institute NSW, University of NSW and SWSLHD.

1.0 FTE radiation oncology clinical trials manager employed by Ingham

1.0 FTE MR physicist is employed by Ingham to work jointly on the Ingham MRI-linac program and the department MR in radiotherapy program (including supporting our dedicated MRI scanner)

1.0 FTE MR engineer is employed by Ingham to work on the MRI-linac program. This position is funded through a collaborative NHMRC program grant.

1.0 FTE postdoctoral medical physics researcher and a part time radiation therapist are employed through the University of Wollongong on a joint Cancer Australia and National Breast Cancer Foundation funded project.

1.0 FTE postdoctoral medical physics researcher is employed through the University of Sydney on a joint Cancer Council funded project.

2.0 FTE postdoctoral computer science researchers are employed through the University of Sydney on a joint project with the University and a number of other hospitals. These positions are funded through a NSW Health bioinformatics proof of concept grant.

1.0 FTE imaging scientist will be employed shortly by the Ingham Institute with funding from the CONCERT NSW cancer institute translational program grant

9

Within the CCORE group there is a 1.0 FTE research project manager and an 1,0 FTE administrative support position, both funded through UNSW.

2.3 Research structure

Research undertaken within the department has developed significantly since the initiation of the department and the research structure has developed in parallel. It is considered important that research and development occur alongside clinical treatment delivery to ensure translation of research findings into practice. There is a supportive environment for research via strong mentorship, available expertise and a broad portfolio of research. Over the previous 5 years we have strengthened research output and future research opportunities by encouraging coordination between the various research groups and collaboration amongst the various radiation oncology disciplines through the establishment of the research executive committee as demonstrated in section 3.1. Our research work is now internationally recognised and there are a number of well-established research project areas. Our department research structure is designed to strengthen these research project areas, provide support for current and future researchers through mentoring and ensure decisions about potential future project areas are aligned with our department goals and resources. With the goal of co-ordinating a growing number of research projects, such that projects can build from each other and that finite resources are allocated and managed in the most effective manner the research executive committee was formed in 2010. The research executive group currently consists of radiation therapy, medical physics, radiation oncology, clinical trials and nursing department heads as well as representative staff from each of the craft groups with a research focus. This committee is responsible for updating the research priority criteria to ensure research resources are allocated effectively. The research executive committee reports to the radiation oncology executive committee. The research executive committee currently has the role of coordinating research projects as well as facilitating training and mentoring to further develop our research potential, including monitoring funding opportunities and mentoring new researchers. As mentioned above the CCORE and MRI-linac research programs have stand-alone oversight and leadership committees but still maintain strong links to the department through the radiation oncology executive committee and other links. Individual projects within these larger programs are also considered by the REC when department resources ( eg staff) are involved. There are also a number of other forums within the department in which research projects are discussed including site specific radiotherapy interest groups, the medical physics research group, the MRI sim group and the clinical trials group.

10

These groups are responsible for initiating research projects in particular focus areas and ensuring regular reporting of project progress and where appropriate translation of research output to the clinic in an effective and efficient manner. All projects initiated by these groups or elsewhere utilising department resources, including staff time, are reviewed by the REC. With the expansion of research within our department, we will be reviewing the most appropriate research governance structure to ensure coordination of and support for research across the department. This will likely involve central coordination within the department to ensure support for all professional groups such that our research vision is achieved in all areas of clinical practice and that opportunities for involvement in research exist for all our staff.

11

Figure 1 Structure of research groups and the reporting structure for research projects utilising the department of radiation oncology Liverpool and Macarthur cancer therapy centre resources, including staff time.

Radiation Oncology Executive Committee

Research Executive Committee (REC)

RT Interest Groups

- Formed to discuss clinical and research projects related to particular clinical areas. - GU, Lung, Breast, Imaging, Gynae/Brachy, and H&N

Physics Research Group

- To provide a

discussion forum for physics based research projects

MRI Simulator Group

- Coordination of projects involving the use of MRI for RT simulation -Chaired by Assoc.Prof Shalini Vinod and includes members from all craft groups in radiation oncology

MRI-Linac Steering

Committee

- Coordination of projects necessary for overall development of MRI-Linac - Chaired by Prof Paul Keall and includes members from a number of collaborating institutions.

CCORE

- This research centre is lead by Prof Michael Barton. -Projects relating to health services research are coordinated within this unit.

Radiation Oncology

Clinical Trials Committee

- Coordination of radiation oncology clinical trials - Chaired by Dr Karen Wong

12

2.4 Research Mentoring for Individuals

One of the key goals of our REC is to encourage and mentor staff who wish to be involved in research. A proposed research training pathway is below. This pathway demonstrates common experiences, possible within our department, that it is useful to undertake before progressing to the next research experience. It should be noted that this pathway does not necessarily need to be followed in order and can often be ‘fast- tracked’ through undertaking a higher research degree, however this path does provide some broad guidance for those who which to develop research skills and those who are mentoring others to develop research skills. To facilitate training in research skills we have also coordinated a series of research training sessions, covering basic research skills. In recent years, a larger research methodology program has been offered by the Ingham Institute and members of our department for whom this is appropriate have been encouraged to attend. Radiation oncology focused research training sessions are still run within the department.

13

1. Research Project experience Involvement in a research project led by someone else.

Usually this would be in an area where the person concerned already has skills and will involve learning about research process, ethics requirements and

presentation/publication (e.g treatment planning, dosimetry measurements, contouring)

2. Presentation and Publication experience Involvement in a presentation led and put together by someone else within the

project. Putting together your own presentation (poster or oral) on your component of the

larger research project Involvement in a publication led and put together by someone else within the project.

3. Developing and undertaking a research project Put together a small research project building on previous work with support from a

more experienced researcher (who will maintain involvement in the project). This should include, involvement with relevant ethics submissions, leading a

presentation and may involve leading a research publication with support from a more experience researcher

4. Research grant submission experience Involvement in a research grant submission led by a more experienced researcher.

Usually this would be in an area where you have already been involved in some research work.

Putting together your own small research grant proposal ( eg Department, Ingham or University grant submissions).

5. Advanced Research Skills Developing and undertaking a major research project where you are the lead researcher, including leading presentations and publications, developing and

coordinating a research team with an appropriate skill mix for the project being considered and necessary ethics submissions including other institutions.

Supervision of other staff or students in research projects

Submitting an external research grant where you are the lead investigator.

For all these activities it is recommended that these are still undertaken with the

involvement of a more senior researcher initially.

14

2.5 Research support for strategic research areas

As well as providing support for staff and students who wish to be involved in research our department is also dedicated to providing necessary support for our areas of research strength. This will ensure that the research profile of our department and SWSLHD in general continues to be recognised and developed nationally and internationally. This will be achieved through providing support for necessary infrastructure for these project areas, encouraging both national and international collaborations to ensure a high level of expertise is available for these projects. Support will also be provided to ensure this research is presented to a national and international audience such that our work is seen by others in a timely fashion and that appropriate feedback is received on this work from international experts. Attendance at national and international meetings will often require more than one member of each professional group to ensure attendance by at least one researcher from each project area.

2.6 Our collaborators

A number of research collaborations have been established between our department and others to strengthen and further develop research projects and opportunities. These collaborators include:

Institution/ Department

Lead Individuals Research Strengths Collaborative

Areas

The Institute of

Medical Physics, The University of

Sydney

Professor David

Thwaites & Associate Professor Zdenka

Kuncic

Data mining, imaging, MRI, radiotherapy dosimetry, radiation physics, and Monte

Carlo modelling

Data mining, radiotherapy

dosimetry, radiation physics, and Monte

Carlo modelling

The Department of Medicine, The University of

Sydney

Professor Paul Keall

Image guided radiation therapy; accounting for anatomic & physiologic

changes in healthy and pathologic tissue during radiotherapy

Image guided radiation therapy

including the MRI-linac development which Prof Keall is

leading

The Centre for Medical Radiation Physics (CRMP), The University of

Wollongong

Professor Anatoly Rosenfeld & Professor

Peter Metcalfe

Radiation dosimetry, Monte Carlo Modelling, radiobiological modelling,

proton therapy and clinical implementation of novel treatment

techniques

Radiation dosimetry, radiobiological

modelling

Nanoscale Organisation and Dynamics Group, The University of Western Sydney

Professor William S. Price

Theoretical and experimental development and application of magnetic resonance based techniques for probing

translational motion (e.g., diffusion)

Development of techniques for establishing

pathology with diffusion imaging

15

The Department of Radiation

Oncology, Calvary Mater Newcastle

Hospital

Dr Peter Greer and Associate Prof Joerg

Lehman, ROs

Radiotherapy dosimetry with existing and novel electronic portal imaging detectors,

adaptive prostate treatment and radiotherapy dosimetry calculations

utilising MR images

Radiotherapy dosimetry with

existing and novel electronic portal

imaging detectors, radiotherapy

dosimetry calculations utilising

MR images

The NSW Radiation Therapy Research Group

Research radiation therapists from NSW

and interstate

To communicate, discuss and collaborate in upcoming and current research and quality assurance projects occurring

within the NSW public and private health system

Collaborative projects

Stanford University, USA

Dr Rebecca Fahrig, Dr Norbett Pelc and others

Diagnostic imaging and imaging reconstruction. Imaging and detector

hardware.

Australian MRI-linac program

MAASTRO, The Netherlands

Prof Andre Dekker Data mining for radiation oncology using

novel approaches to harnessing knowledge from big clinical data

Data mining

University of Queensland

Prof Stuart Crozier MRI engineering Australian MRI-linac

program

Trans Tasman Radiation

Oncology Group many Radiotherapy clinical trials

A number of radiotherapy clinical

trials

Other National Radiation Oncology

Departments

Many departments leading clinical trials or

involved in other collaborative research

Enthusiasm for clinical trials or research studies

Clinical trials and other research

studies including the MRI-linac, MR in RT

research, Uncertainties in

radiotherapy and Data mining

Other International Radiation Oncology

Departments including the University of

Odense, Henry Ford Clinic Detroit, University of Oslo,

University of Wisconsin

Many different individuals

Enthusiasm for clinical trials or research studies

MRI in radiotherapy, Uncertainties in radiotherapy,

radiation dosimetry

CSIRO Dr Jason Dowling Image processing

MRI-linac program, MR in RT,

Radiotherapy Uncertainties

16

3. Our Objectives

3.1 Achievements and Challenges from our previous strategic plan (2011-2015)

Assessment of our 2011-2015 objectives

Objective Key performance indicators

1. Achieve high quality research Number and citation numbers of publications: see attached list

Number of presentations and impact of conferences: see attached list

2. Provide high quality research training and mentoring

Number of successful higher degree students: 8 PhDs and 18 masters degrees completed.

Over 50 % of staff are involved in research projects

3. Attract and maintain high quality staff and students

Available research positions filled: We have increased our research staff over this time, many externally grant funded and have filled all available positions.

4. Attract external funding to achieve on-going research

Our department has been involved in successful research grant submissions totalling over $20 million.

5. Facilitate and strengthen research collaborations

Collaborative grant submissions and publications: Over 20 grants with collaborators were funded. Over 80% of publications were with collaborators. Of note there are more publications and grants with collaborating groups than without.

6. Develop recognised world leading status in a limited number of chosen areas

Over 70 invited national and international presentation invitations have been received.

7. Consumer Involvement in research projects

Consumer involvement in key research projects: We have consumer involvement in many major research projects. This is not the case for smaller projects. Together with others at Ingham we have established the Ingham Cancer

17

Community Research Review Panel to facilitate consumer involvement with research projects.

Consumer involvement in grant submissions We have consumer involvement in almost all grant submissions.

8. Incorporation of research developments into clinical practice

Research outcomes implemented into clinical studies and then standard clinical practice in a timely fashion. REC is reviewing all research projects to ensure support for clinical implementation where appropriate. Clinical implementation and impact has been demonstrated with implementation of VMAT, streamlined quality assurance processes and implementation of change in treatment practice due to a number of clinical trials.

Strategies for success with this strategic plan

Establishment and growth of the Ingham Institute, particularly the availability of the research building and the research linear accelerator bunker, providing dedicated resources and physical space for our research work.

Significant input from highly experienced external collaborators (eg Prof Paul Keall, Prof David Thwaites). This has provided mentoring for senior members of our research team as well as support for research programs and grant submissions.

Opportunities to collaborate on both the local and international scale (eg Prof Andre Dekker from MAASTRO, The Netherlands coming to visit). This has strengthened research opportunities dramatically with the majority of research projects now being undertaken in a collaborative fashion.

Research management from dedicated staff (eg dedicated research physicist and RTs whose primary role is to promote and facilitate research. This is in contrast to other centres where this has to be undertaken by someone who also has to prioritise clinical activities)

Active support for those undertaking research degrees, especially PhDs. A number of small top-up scholarships have been offered to attract high calibre research students. This has added extra dedicated personnel to our research teams and has increased motivation and enthusiasm from others involved in their projects.

Support from the radiation oncology trust fund for research personnel, research equipment, conference attendance and collaborative visits.

18

Support from ethics in streamlined meta-project review for retrospective low and negligible risk projects involving treatment planning and imaging comparisons.

Challenges in implementing this strategic plan:

Research projects and associated research output has grown and this is now a major administrative challenge without dedicated resources.

There was also high turnover in the administration positions that provided some limited support. As support for research projects is different to that required for clinical activities this results in significant training time for these staff often with very little practical benefit as they then move positions.

There have been a number of challenges in achieving support for more than one staff member from a given craft group to attend international conferences. When only a single staff member is supported to attend such a conference it is impossible to present on and learn about research being undertaken across all areas of our research program. There are also many missed collaborative and networking opportunities. This is especially the case for large conferences where there are multiple concurrent research streams.

Challenges in training more junior researchers while still providing clinical services. The recently implemented early and mid-career research scheme is an excellent initiative that will improve this over coming years.

Flexibility with researchers’ time is often challenging. This is particularly necessary for collaborative projects requiring travel or after hours interactions with international collaborators and when after hours access is required to clinical equipment.

There have been challenges in obtaining-ethics approval for many of our technology focused research projects which has resulted in delayed start of research. The ethics department have been very supportive in trying to improve this however this is something that together we need to work to improve further.

Over the majority of this time period we have had limited resources available for radiation oncology clinical trials. This has resulted in delays in starting external clinical trials that we are involved with and a lack of initiation of local clinical trials. Since the employment of a dedicated radiation oncology clinical trials team this has improved dramatically and we expect will continue to improve.

Developing a research culture embedded across all work groups has been a challenge. There have been major successes in some groups but we recognise there is more to achieve in particular work groups.

19

3.2 Key objectives to achieve our vision for 2015-2020

Objective Alignment with

SWSLHD research aims

Key performance indicators

How this will be achieved

1. Achieve high quality research

This objective aligns with the SWSLHD aim to Strengthen the quality and quantity of research in the SWSLHD.

The number of international and national publications from our department

The impact factor and citation numbers of publications from our department

The number of presentations (especially invited) at highly recognised national and international conferences

Provide support for the research governance structure and further develop this structure and leadership as necessary

By ensuring all the following objectives are met.

2.Further develop our research governance structure

This objective aligns with the SWSLHD aim to Develop governance arrangements which ensure accountability and responsibility for research conducted according to ethical principles, scientific, regulatory and professional standards and the principles of risk management.

Completed review and if necessary implementation of changes to our current governance structure

Review terms of reference for the research executive committee and review our support structure for research staff.

3.Provide high quality research

This objective aligns with the

Number of successful higher

Continued research education and

20

training and mentoring

SWSLHD aim to Encourage new researchers, including junior staff, and, sustain the commitment to research of SWSLHD personnel in management, support and research roles.

degree students

Number of staff involved in research activities

Number of staff developing increased research expertise

training programs, as facilitated through the RT education program or similar programs.

Continued collaboration with universities to facilitate research projects successfully undertaken within our department

Continued offer of research mentorship and support for those involved.

4.Attract and maintain high quality staff and students

This objective aligns with the SWSLHD aim to Strengthen the quality and quantity of research in the SWSLHD.

Research and clinical positions filled

Discuss funding and recruitment opportunities as they arise.

Achievement of objective 1.

Continued scholarships to attract high quality university research students

Appropriate advertising and networking to fill available research and clinical positions

Opportunities to set-up short term positions where high quality students have completed their training

Conditions of employment such that staff are attracted to work here and to continue working here. This will include facilitation of ongoing support for conference travel and education opportunities for those achieving high quality research.

High profile research projects such

21

as the MRI linac project

5.Attract external funding to achieve on-going research

This objective aligns with the SWSLHD aim to Identify resourcing required to implement the strategies in the Plan and potential sources of funding.

Submission of grants

Successful grant applications

Mentoring for those interested in writing grant application development and submission

Administrative support for those submitting grant applications

Provision of necessary scientific support, such as statistical support and clinical trials support for those submitting grant applications

Monitoring of grant opportunities

Look for industry and philanthropic support opportunities

6.Facilitate and strengthen research collaborations

This objective aligns with the SWSLHD aim to Support and further develop the capacity for research across the SWSLHD.

Collaboration between radiation oncology and other departments within the hospital and at Ingham.

Collaborative grant submissions and publications

Collaborations with industry

Initiation of multicentre research studies

Visits from high quality researchers to Liverpool and

Support (funding and time available) for visits from current and potential collaborators

Support (funding and time available) for visits to current and potential collaborators

Support for collaborative grant submissions and publications

Support for industry collaborations

Support for joint research projects (including student projects) between our

22

Macarthur and visits to other national and international high quality research institutions by our staff

department and other SWSLHD departments

7.Develop recognised world leading status in a limited number of chosen areas

This objective aligns with the SWSLHD aim to Enhance the profile of current research in the SWSLHD.

Highly cited publications in chosen areas

Presentations and attendance at major national and international meetings

Invitations to present at significant national and international meetings in chosen areas

Prioritising research areas within the department, as detailed below

Allocating research resources according to these priorities

Providing education opportunities for those involved and potentially involved in research in these areas.

Ensuring key research areas are presented at major national and international conferences in a timely fashion.

8.Undertake high quality clinical trials

This objective aligns with the SWSLHD aim to Strengthen the quality and quantity of research in the SWSLHD.

Initiation of multicentre research studies from within our centre.

Commencement and recruitment for externally initiated clinical trials where appropriate.

Providing high quality clinical trial support and mentoring.

Providing research opportunities (such as the MR sim) appropriate for clinical trials.

Providing support for collaborations on clinical trials with other institutions.

9.Consumer Involvement in research

This objective aligns with the SWSLHD aim to

Continued consumer involvement in our

Support for the Ingham Institute community cancer

23

projects Ensure structures support creativity and lead to research which improves health and health service provision.

research projects

Consumer involvement in key research projects

Consumer involvement in grant submissions

research panel, including support for the consumers on this panel where necessary.

Facilitation and support for, particularly larger research projects, to have a consumer representative.

10.Translation of research developments into clinical practice

This objective aligns with the SWSLHD aim to Ensure structures support creativity and lead to research which improves health and health service provision.

Research outcomes implemented into clinical studies and then standard clinical practice in a timely fashion.

Encouraging involvement of staff in research activities to build skill levels with new technologies and techniques

Allocation of resources for these research projects to continue into the clinic.

4. Priority research areas 2015-2020 Resources and infrastructure will be allocated within our department to support the following research areas in the following priority order. This order may be updated by the research executive committee if department priorities change over this time frame. Details of the various research areas are given in section 2.1.

1. Australian MRI-linac program

2. Health Services Research

3. MRI-simulator projects

5. Projects related to clinical priority areas

6. Clinical Trials

7. Other established research areas or with external funding

24

As listed in section 2 including Survivorship research, Uncertainties in radiotherapy, Data mining, Radiation dosimetry, Imaging in radiotherapy including PET

8. Other areas of research without external funding

Other areas of research will be supported when resources are still available following allocation to the above areas.

Appendix

Table of Contents Publication list ..................................................................................................................................... 2

Journal publications ........................................................................................................................ 2

Book Sections ................................................................................................................................ 11

Grants ................................................................................................................................................ 12

Clinical Trials ..................................................................................................................................... 16

Invited presentations ........................................................................................................................ 18

Awards .............................................................................................................................................. 23

1

Publication list

Journal publications

1. Arnold A, Delaney GPP, Cassapi L, Barton M. The use of categorized time-trend reporting of radiation oncology incidents: a proactive analytical approach to improving quality and safety over time. IntJ RadiatOncolBiolPhys. 2010;78:1548-54.

2. Arumugam S, Jameson MG, Xing A, Holloway L. An accuracy assessment of different rigid body image registration methods and robotic couch positional corrections using a novel phantom. MedPhys. 2013;40:031701.

3. Arumugam S, Xing A, Goozee G, Holloway L. Independent calculation-based verification of IMRT plans using a 3D dose-calculation engine. Medical Dosimetry. 2014;38:376-84.

4. Arumugam S, Xing A, Jameson M, Holloway L. An algorithm to calculate a collapsed arc dose matrix in volumetric modulated arc therapy. MedPhys. 2013;40:071724.

5. Arumugam S, Young T, Xing A, Holloway L. What VMAT Delivery Errors Can Be Detected with Commercial Dosimetric Systems? A Comparison of Three Dosimetric Systems. Medical Physics. 2013;40:432-.

6. Ball D, Fisher R, Burmeister BH, Poulsen M, Graham P, Penniment M, Vinod SK, Krawitz H, Wheeler G, McClure B. The complex relationship between lung tumour volume to survival in patients with non-small cell lung cancer (NSCLC) treated by definitive radiotherapy (TROG Study 9905). Journal of Medical Imaging and Radiation Oncology. 2010;53:A108.

7. Barton M, Delaney GPP. A decade of investment in radiotherapy in New South Wales: why does the gap between optimal and actual persist? J MedImaging RadiatOncol. 2011;55:433-41.

8. Barton M, Thode RJ. Distance learning in the Applied Sciences of Oncology. RadiotherOncol. 2010;95:129-32.

9. Barton M. Medical Mentor: Prof Michael Barton reflects on his career in Radiation Oncology. Medical Journal of Australia. 2011:C5-C.

10. Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney GPP. Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012. RadiotherOncol. 2014;112:140-4.

11. Batumalai V, Jameson MG, Forstner DF, Vial P, Holloway LC. How important is dosimetrist experience for intensity modulated radiation therapy? A comparative analysis of a head and neck case. Pract RadiatOncol. 2013;3:e99-e106.

12. Batumalai V, Koh ES, Delaney GPP, Holloway LC, Jameson MG, Papadatos G, Lonergan DM. Interobserver variability in clinical target volume delineation in tangential breast irradiation: a comparison between radiation oncologists and radiation therapists. ClinOncol(RCollRadiol). 2011;23:108-13.

13. Batumulai V, Jameson M, Holloway LC, Forstner D, Fowler A, Nguyen C. Dosimetric considerations and optimal replanning strategies for H&N IMRT. Radiotherapy and Oncology. 2010;96:S101.

14. Bawazeer O, Gray A, Arumugam S, Vial P, Thwaites D, Descallar J, Holloway L. Evaluation of the ability of a 2D ionisation chamber array and an EPID to detect systematic delivery errors in IMRT plans. Journal of Physics: Conference Series. 2014;489:012071.

2

15. Begg J, Taylor ML, Holloway L, Kron T, Franich RD. Effect of light source instability on uniformity of 3D reconstructions from a cone beam optical CT scanner. AustralasPhysEng SciMed. 2014.

16. Bell LJ, Oliver L, Vial P, Eade TN, Rinks M, Hammond E, Morgan GW, Back M, Wiltshire KL. Implementation of an image-guided radiation therapy program: Lessons learnt and future challenges. J MedImaging RadiatOncol. 2010;54:82-9.

17. Blake S, McNamara A, Vial P, Holloway L, Kuncic Z. Optimisation of the imaging and dosimetric characteristics of an electronic portal imaging device employing plastic scintillating fibres using Monte Carlo simulations. Physics in medicine and biology. 2014;59:6827.

18. Blake SJ, McNamara AL, Deshpande S, Holloway L, Greer PB, Kuncic Z, Vial P. Characterization of a novel EPID designed for simultaneous imaging and dose verification in radiotherapy. Medical Physics. 2013;40:091902.

19. Blake SJ, Vial P, Holloway L, Greer PB, McNamara AL, Kuncic Z. Characterization of optical transport effects on EPID dosimetry using Geant4. Medical Physics. 2013;40:041708.

20. Boxer M, Vinod SK, Shafiq J, Duggan KJ. Do multidisciplinary team meetings make a difference in the management of lung cancer? Cancer 2011. 2011;117:5112-20.

21. Boxer MM, Delaney GPP, Chua BH. A review of the management of ductal carcinoma in situ following breast conserving surgery. Breast. 2013;22:1019-25.

22. Carter HE, Martin A, Schofield D, Duchesne G, Haworth A, Hornby C, Sidhom M, Jackson M. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiotherapy and Oncology. 2014;112:187-93.

23. Chambers SK, Baade P, Youl P, Aitken J, Occhipinti S, Vinod S, Valery PC, Garvey G, Fong KM, Ball D. Psychological distress and quality of life in lung cancer: the role of health-related stigma, illness appraisals and social constraints. Psycho-Oncology. 2015.

24. Cheema BS, Kilbreath SL, Fahey PP, Delaney GPP, Atlantis E. Safety and efficacy of progressive resistance training in breast cancer: a systematic review and meta-analysis. Breast Cancer ResTreat. 2014;148:249-68.

25. Christie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G. Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. IntJ RadiatOncolBiolPhys. 2011;80:1164-70.

26. Concha OP, Gallego B, Hillman K, Delaney GPP, Coiera E. Do variations in hospital mortality patterns after weekend admission reflect reduced quality of care or different patient cohorts? A population-based study. BMJ QualSaf. 2014;23:215-22.

27. Constantin DE, Holloway L, Keall PJ, Fahrig R. A novel electron gun for inline MRI-linac configurations. MedPhys. 2014;41:022301.

28. Dall'Armi L, Simpson GK, Forstner D, Simpson T, Roydhouse JK, White KJ. The information needs of patients with head and neck cancer and their caregivers: a short report of instrument development and testing. ApplNursRes. 2013;26:40-4.

29. De Leon J, Jameson M, Windsor AA, Cloak K, Keats S, Vial P, Holloway L, Metcalfe P, Sidhom M. Superior target volume and organ stability with the use of Endorectal Balloons in Post Prostatectomy Radiotherapy. JMIRO. 2015:accepted Feb 2015.

3

30. Dekker A, Vinod S, Holloway L, Oberije C, George A, Goozee G, Delaney GPP, Lambin P, Thwaites D. Rapid learning in practice: a lung cancer survival decision support system in routine patient care data. RadiotherOncol. 2014;113:47-53.

31. Delaney GPP, Barton MB, Noble D. Radiotherapy: using risk profiling to identify errors and clsoe calls in the process of care. Joint Commission Resources. 2011:103-10.

32. Deshpande S, McNamara AL, Holloway L, Metcalfe P, Vial P. Feasibility study of a dual detector configuration concept for simultaneous megavoltage imaging and dose verification in radiotherapy. Medical Physics. 2015:accepted Jan 2015.

33. Deshpande S, Vial P, Holloway LC. 2-D radition therapy dosimetry using EPIDs: Dose response variation between 3 siemens electronic portal imaging devices (EPIDs). Radiation Measurements. 2012.

34. Deshpande S, Xing A, Holloway L, Metcalfe P, Vial P. Dose calibration of EPIDs for segmented IMRT dosimetry. Journal of Applied Clinical Medical Physics. 2014;15.

35. Fong A, Ng W, Barton M. Estimation of an evidence-based benchmark for the optimal endocrine therapy utilization rate in breast cancer. The Breast. 2010;E publication.

36. Fong A, Shafiq J, Saunders C, Thompson A, Tyldesley S, Olivotto IA, Barton MB, Dewar JA, Jacob S, Ng W, Speers C, Delaney GPP. A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy. Breast. 2012;21:562-9.

37. Fong A, Shafiq J, Saunders C, Thompson AM, Tyldesley S, Olivotto IA, Barton MB, Dewar JA, Jacob S, Ng W, Speers C, Delaney GPP. A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy. Breast. 2012;21:570-7.

38. Fong A, Shafiq J, Tyldesley S, Thompson AM, Saunders C, Dewar JA, Ng W, Jacob S, Speers C, Olivotto I, Delaney GPP. A Systemic Breast Cancer Therapy Utilization in Canada (British Columbia), Scotland and Western Asutralia with Models of "Optimal" Therapy. The Breast. 2012.

39. G.P. Liney, JE Marsden, CJ Horsfield, T Murray, DJ Manton, A.W. Beavis. Improved visualisation of cervix applicators for MR only guided brachytherapy planning. J Radiotherapy in Practice 2014; 13:159-165.

40. G.P. Liney, MA Moerland. Magnetic resonance imaging acquisition techniques for radiotherapy planning. Semin Radiat Oncol 2014; 160-168.

41. G.P. Liney, S.C. Owen, A.K.E. Beaumont, V.R. Lazar, D.J. Manton, A.W. Beavis. Commissioning of a new wide-bore MRI scanner for radiotherapy planning of head and neck cancer. Br J Radiol 2013; 86:20130150

42. Ghose S, Holloway L, Lim K, Veera J, Vinod SK, Liney G, Greer P, Dowling J. A review of segmentation and deformable registration methods applied to adaptive cervical cancer radiation therapy treatment planning Artificial Intelligence in Medicine. 2015:accepted April 2015.

43. Girgis A, Delaney GPP, Arnold A, Carelan M, Della-Fiorentina S, Kaadan N, Avery S, Domburg N, Ng W, et al. Translating evidence into practice through the PROMPT-Care project: Utilsing Patient Reported Outcome Measures for Personalised Cancer Treatment and Care. Psycho Oncology. 2014;23:256-7.

44. Girgis A, Delaney GPP, Arnold A, Miller A, Carolan M, Della-Fiorentina S, Kaadan N, Avery S, Domburg N, Ng W, et al. The Prompt-Care project: E-Health system utilising patient reported

4

outcoms to inform personalised cancer treatment and care. Asia-Pacific Journal of Clinical Oncology. 2014;10:21-.

45. Gladwish A, Koh ES, Hoisak J, Lockwood G, Millar BA, Mason W, Yu E, Laperriere NJ, Menard C. Evaluation of early imaging response criteria in glioblastoma multiforme. RadiatOncol. 2011;6:121.

46. Goldsbury D, Harris M, Pascoe S, Barton M, Olver I, Spigelman A, Beilby J, Veitch C, Weller D, O'Connell DL. The varying role of the GP in the pathway between colonoscopy and surgery for colorectal cancer: a retrospective cohort study. BMJ Open. 2013;3.

47. Graham PH, Plant N, Graham JL, Browne L, Borg M, Capp A, Delaney GPP, Harvey J, Kenny L, Francis M, Zissiadis Y. A Paired, Double-Blind, Randomized Comparison of a Moisturizing Durable Barrier Cream to 10% Glycerine Cream in the Prophylactic Management of Postmastectomy Irradiation Skin Care: Trans Tasman Radiation Oncology Group (TROG) 04.01. Int J RadiatOncol BiolPhys. 2013.

48. Graham PH, Plant NA, Graham JL, Browne LH, Borg M, Capp A, Delaney GPP, Harvey J, Kenny L, Francis M, Zissiadis Y. Digital photography as source documentation of skin toxicity: An analysis from the Trans Tasman Radiation Oncology Group (TROG) 04.01 Post-Mastectomy Radiation Skin Care Trial. J Med Imaging RadiatOncol. 2012;56:458-63.

49. Gustafsson H, Vial P, Kuncic Z, Baldock C, Denham JW, Greer PB. Direct dose to water dosimetry for pretreatment IMRT verification using a modified EPID. Med Phys. 2011;38:6257-64.

50. Hanna TP, Shafiq J, Delaney GPP, Barton MB. An estimation of the population benefit of radiotherapy for cervical cancer: local control and survival. Journal of Medical Imaging and Radiation Oncology. 2012.

51. HannaTP, Delaney GPP, Barton MB. The population benefit of radiotherapy for gynaecological malignancies: local control and survival estimates for optimally utilized radiotherapy and chemoradiation. Journal of Medical Imaging and Radiation Oncology. 2012.

52. Hau E, Browne L, Capp A, Delaney GPP, Fox C, Kearsley JH, Millar E, Nasser EH, Papadatos G, Graham PH. The impact of breast cosmetic and functional outcomes on quality of life: long-term results from the St. George and Wollongong randomized breast boost trial. Breast Cancer ResTreat. 2013;139:115-23.

53. Hayden AJ, Martin JM, Kneebone AB, Lehman M, Wiltshire KL, Skala M, Christie D, Vial P, McDowall R, Tai KH. Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma. J MedImaging RadiatOncol. 2010;54:513-25.

54. Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, Baldock C. Advances in kilovoltage x-ray beam dosimetry. Physics in Medicine and Biology. 2014;59:R183.

55. Holloway L, Batumalai V, Moran V, Liney G, Koh ES, Lazarus E, Dimigen M, Papadatos G, Boxer M, Chan C, Delaney GPP. Comparison of Prone and Supine MRI Sequences for the Purpose of Radiotherapy Treatment Planning for Breast Cancer. Medical Physics. 2013;40:191-.

56. Holloway LC, Jameson M, Batumalai V, Koh ES, Delaney GPP. Estimating a Delineation Uncertainty Margin to Account for Inter-observer Variability in Breast Cancer Radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2010;78:S741.

5

57. Holloway LC, Miller JA, Kumar S, Whelan BM, Vinod SK. Comp Plan: A computer program to generate dose and radiobiological metrics from dose-volume histogram files. MedDosim. 2012.

58. Hong AM, Dobbins TA, Lee CS, Jones D, Fei J, Clark JR, Armstrong BK, Harnett GB, Milross CG, Tran N, Peculis LD, Ng C, Milne AG, Loo C, Hughes LJ, Forstner DF, O'Brien CJ, Rose BR. Use of cyclin D1 in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer. IntJ Cancer. 2011;128:1532-45.

59. Hovey E, Koh ES, Jeffree L, Cole A. How to Treat: Malignant Glioma in Adults. Australiandoctorcomau. 2010.

60. Hughes J, Holloway LC, Quinn A, Fielding A. An investigation into factors affecting electron density calibration for a megavoltage cone-beam CT system. J ApplClin Med Phys. 2012;13:3271.

61. Jacob S, Hovey E, Ng W, Vinod S, Delaney GPP, Barton MB. Estimation of an optimal chemotherapy utilisation rate for lung cancer: an evidence-based benchmark for cancer care. Lung Cancer. 2010;69:307-14.

62. Jacob S, Ng W, Asghari R, Delaney GPP, Barton MB. Chemotherapy in rectal cancer: variation in utilization and development of an evidence-based benchmark rate of optimal chemotherapy utilization. ClinColorectal Cancer. 2011;10:102-7.

63. Jacob S, Ng W, Delaney GPP, Barton MB. Estimation of an optimal chemotherapy utilisation rate for primary malignant brain tumours: an evidence-based benchmark for cancer care. ClinOncol(RCollRadiol). 2011;23:48-54.

64. Jacob S, Wong K, Delaney GPP, Adams P, Barton MB. Estimation of an optimal utilisation rate for palliative radiotherapy in newly diagnosed cancer patients. ClinOncol(RCollRadiol). 2010;22:56-64.

65. Jameson M, Batumalai V, Holloway LC, Forstner D, Fowler A, Nguyen C. When to replan? A quantitative approach to adaptive therapy. Radiotherapy and Oncology. 2010;96:S235.

66. Jameson M, Holloway LC, Vial PJ, Vinod SK, Metcalfe PE. A review of methods of analysis in contouring studies for radiation oncology. J MedImaging RadiatOncol. 2010;54:401-10.

67. Jameson M, Ohanessian L, Batumalai V, Patel V, Holloway L. Comparison of Oncentra® Brachy IPSA and graphicaloptimisation techniques: a case study of HDRbrachytherapy head and neck and prostate plans. Journal of Medical Radiation Sciences. 2015:accepted April 2015.

68. Jameson MG, De Leon J, Windsor AA, Cloak K, Keats S, Dowling JA, Chandra SS, Vial P, Sidhom M, Holloway L. Endorectal balloons in the post prostatectomy setting: Do gains in stability lead to more predictable dosimetry? Radiotherapy and Oncology. 2013;109:493-7.

69. Jameson MG, Kumar S, Vinod SK, Metcalfe PE, Holloway LC. Correlation of contouring variation with modeled outcome for conformal non-small cell lung cancer radiotherapy. RadiotherOncol. 2014.

70. Johnston ML, Vial P, Wiltshire KL, Bell LJ, Blome S, Kerestes Z, Morgan GW, O'Driscoll D, Shakespeare TP, Eade TN. Daily Online Bony Correction is Required for Prostate Patients Without Fiducial Markers or Soft-tissue Imaging. ClinOncol(RCollRadiol). 2011;23:454-9.

71. Kang S, Koh ES, Vinod SK, Jalaludin B. Cost analysis of lung cancer management in South Western Sydney. J Med Imaging RadiatOncol. 2012;56:235-41.

6

72. Ke H, Koh ES, Simpson GK, Gillett L. Comparison of the Montreal Cognitive Assessment and Mini-Mental State Examination as cognitive screens for primary brain tumor. Brain Injury. 2013.

73. Kenny LM, Peters LJ, Barton M, Millross C. Radiotherapy - a leap forwarded in cancer care. Cancer Forum. 2013;37.

74. Kumar S, Juresic E, Barton M, Shafiq J. Management of skin toxicity during radiation therapy: a review of the evidence. J MedImaging RadiatOncol. 2010;54:264-79.

75. Lehman M, Hayden AJ, Martin JM, Christie D, Kneebone AB, Sidhom M, Skala M, Tai KH. FROGG high-risk prostate cancer workshop: Patterns of practice and literature review. Journal of medical imaging and radiation oncology. 2014;58:257-65.

76. Lim S DJ, Sayaloune P, Delaney GPP, Papadatos G, DeSouza P. Correlation of Grade and hormone-receptor status with stage in node-positive, non metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology. 2012;8:335-.

77. Lim SH, Chua W, Chen C, Descallar J, Ng w L, Solomon M, Bokey L, Wong K, Lee MT, DeSouza P, Shin JS, Lee CS. Effect of Neoadjuvant Chemoradiation on Tumour Infiltrating/Associated Lymphotcytes in Locally Advanced Rectal Cancers. Anticancer Research 2014. 2014.

78. Lim SH, Delaney GPP, Descallar J, Sayaloune P, Papadatos G, de SP. Outcomes of ethnic minority groups with node-positive, non-metastatic breast cancer in two tertiary referral centers in Sydney, Australia. PLoSOne. 2014;9:e95852.

79. Lin M, Wong K, Ng WL, Shon IH, Morgan M. Positron emission tomography and colorectal cancer. Crit RevOncolHematol. 2011;77:30-47.

80. Lin P, Koh ES, Lin M, Vinod SK, Ho-Shon I, Yap M, Som S. Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer. Radiation Oncology 2011. 2011;101:284-90.

81. Liney G, Holloway L, Al-Harthi T, Sidhom M, Moses D, Juresic E, Rai R, Manton D. Quantitative evaluation of diffusion-weighted imaging techniques for the purposes of radiotherapy planning in the prostate. British Journal of Radiology. 2015:accepted March 2015.

82. Lwin Z, Broom A, Cosman R, Livingstone A, Sawkins K, Good P, Kirby E, Koh ES, Hovey E. Culturally and Linguistically Diverse patient participation in glioma research. Neuro-Oncology Practice. 2014.

83. Lwin Z, Broom A, Cosman R, Livingstone A, Sawkins K, Good P, Kirby E, Koh E-S, Hovey E. Culturally and linguistically diverse patient participation in glioma research. Neuro-Oncology Practice. 2014:npu009.

84. M. Al S’ad, J. Graham, G.P. Liney, C. Moore. Quantitative comparison of 3D and 2.5D gamma analysis:introducing gamma angle histograms, Phys. Med. Biol. 2013; 58:2597-2608. IF = 2.83

85. Metcalfe P, Liney GP, Holloway L, Walker A, Barton M, Delaney GPP, Vinod S, Tome W. The potential for an enhanced role for MRI in radiation-therapy treatment planning. TechnolCancer ResTreat. 2013;12:429-46.

86. Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney GP, Fox C, Nasser E, Capp A, Sutherland RL. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. BrJ Cancer. 2011;105:272-80.

87. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, Nasser E, Kearsley J, Delaney GPP, Papadatos G, Fox C, Sutherland

7

R. Prediction of local recurrence, distant metastases and death following breast-conserving therapy in early-stage invasive breast cancer using a five biomarker panel. Clinical Oncology. 2010.

88. Morarji K, Fowler A, Vinod SK, Ho SI, Laurence JM. Impact of FDG-PET on lung cancer delineation for radiotherapy. J Med Imaging RadiatOncol. 2012;56:195-203.

89. Morgan G, Barton M, Atkinson C, Millar J, Kumar GN, Yeoh E. 'GAP' in radiotherapy services in Australia and New Zealand in 2009. J MedImaging RadiatOncol. 2010;54:287-97.

90. Nelson V, Deshpande S, Gray A, Vial P, Holloway L. Comparison of digitally reconstructed radiographs generated from axial and helical CT scanning modes: a phantom study. AustralasPhysEng SciMed. 2014;37:285-90.

91. Ng W, Delaney GPP, Jacob S, Barton MB. Estimation of an optimal chemotherapy utilisation rate for breast cancer: setting an evidence-based benchmark for the best-quality cancer care. EurJCancer. 2010;46:703-12.

92. Ng W, Jacob S, Delaney GP, Barton M. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care. EurJ Cancer. 2009;45:2150-9.

93. Ng W, Jacob S, Delaney GPP, Barton M. Chemotherapy in head and neck cancers: Summary of recommendations and a critical review of clinical practice guidelines. European Journal of Clinical & Medical Oncology. 2010;2:65-71.

94. Pramana A, Descallar J, Vinod SK. A decade of community-based outcomes of patients treated with curative radiotherapy with or without chemotherapy for non-small cell lung cancer. Asia PacJClinOncol. 2014.

95. Quinn A, Holloway L, Begg J, Nelson V, Metcalfe P. Kilovoltage cone-beam CT imaging dose during breast radiotherapy: a dose comparison between a left and right breast setup. MedDosim. 2014;39:190-3.

96. Quinn A, Holloway L, Cutajar D, Hardcastle N, Rosenfeld A, Metcalfe P. Megavoltage cone beam CT near surface dose measurements: potential implications for breast radiotherapy. Med Phys. 2011;38:6222-7.

97. Quinn A, Holloway L, Hardcastle N, Tome WA, Rosenfeld A, Metcalfe P. Normal tissue dose and second cancer risk due to megavoltage fan-beam CT, static tomotherapy and helical tomotherapy in breast radiotherapy. RadiotherOncol. 2013;108:266-8.

98. Quinn A, Holloway L, Koh ES, Delaney GPP, Arumugam S, Goozee G, Metcalfe P. Radiation dose and contralateral breast cancer risk associated with megavoltage cone-beam computed tomographic image verification in breast radiation therapy. Practical Radiation Oncology. 2013;3:93-100.

99. Quinn A, Holloway LC, Koh ES, Arumugam S, Delaney GPP, Batumalai V, Nelson V, Owen K, Goozee G, Vial P, Metcalfe P. Estimating the risks associated with breast radiotherapy and mega-voltage cone-beam CT imaging verification. British Journal of Radiology. 2011.

100. Quinn A, Holloway LC, Koh ES, Arumugam S, Delaney GPP, Batumalai V, Nelson V, Owen K, Goozee G, Vial P, Metcalfe P. Estimating the risks associated with breast radiotherapy and mega-voltage cone-beam CT imaging verification. Practical Radiation Oncology. 2013.

101. Rodin D, Yap ML, Hanna TP. GlobalRT: building a new radiotherapy community. Lancet Oncol. 2014;15:926.

8

102. S. Ipsen, O. Blanck, B. Oborn, F. Bode, G.P. Liney, P. Hunold, D. Rades, A. Schweikard, P. Keal. Radiotherapy beyond cancer: Target localization in real-time MRI and treatment planning for cardiac radiosurgery. Med. Phys. 2014; 41:1-8.

103. Sabet M, Rowshanfarzad P, Vial P, Menk FW, Greer PB. Transit dosimetry in IMRT with an a-Si EPID in direct detection configuration. PhysMed Biol. 2012;57:N295-N306.

104. Sam S, Shon IH, Vinod SK, Lin P, Lin M. Workflow and Radiation Safety Implications of 18F-FDG PET/CT Scans for Radiotherapy Planning. J NuclMed Technol2012. 2012;40:175-7.

105. Shafiq J, Boxer M, Vinod SK, Duggan K. Management of advanced stage non small cell lung cancer (NSCLC) patients presented in multi-disciplinary team (MDT) meetings. Asia-Pacific Journal of Clinical Oncology 2010. 2010;6:100-47.

106. Spigelman AD, Pascoe SW, Harris MF, Beilby JJ, Crossland LJ, Gett RM, Barton MB, Jayasinghe UW. Referral pathways in colorectal cancer: an audit of surgeons's records. AustHealth Rev. 2013;37:449-52.

107. Stebbing J, Delaney GP, Thompson A. Breast cancer (non-metastatic). ClinEvid(Online). 2011;2011.

108. Thompson SR, Delaney GPP, Gabriel G, Jacob S, Das P, Barton MB. Estimation of the Optimal Brachytherapy Utilization Rate in the treatment of vaginal cancers. J Medical Imaging and Radiation Oncology 2012. 2012.

109. Thompson SR, Delaney GPP, Gabriel GS, Barton MB. Patterns of care study of brachytherapy in New South Wales: cervical cancer treatment quality depends on caseload. JContempBrachytherapy. 2014;6:28-32.

110. Thompson SR, Delaney GPP, Gabriel GS, Jacob S, Barton MB. Estimation of the optimal brachytherapy utilisation rate in the treatment of vaginal cancer and comparison with patterns of care. J Med Imaging RadiatOncol. 2012;56:483-9.

111. Thompson SR, Delaney GPP, Gabriel GS, Jacob S, Das P, Barton MB. Estimation of the Optimal Brachytherapy Utilization Rate in the Treatment of Gynecological Cancers and Comparison With Patterns of Care. Int J RadiatOncol BiolPhys. 2012.

112. Tyldesley S, Delaney GP, Foroudi F, Barbera L, Kerba M, Mackillop W. Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. IntJ RadiatOncolBiolPhys. 2011;79:1507-15.

113. Vinod SK, Ball DL. Radiotherapy in Lung Cancer. Cancer Forum. 2013;37:153-7. 114. Vinod SK, Caldwell K, Lau A, Fowler AR. A comparison of ICRU point doses and volumetric

doses of organs at risk (OARs) in brachytherapy for cervical cancer. J MedImaging RadiatOncol2011. 2011;55:304-10.

115. Vinod SK, Goldsbury D, Simonella L, Delaney GPP, O'Connell D. Underutilisation of radiotherapy for lung cancer radiotherapy in NSW Australia. Cancer. 2010;116:686-94.

116. Vinod SK, Holloway LC, Prasad S, McKibbin C, Andrew K, Blakeney S, Franji I, Shafiq J, Koh ES, Fuller M. Dosimetric implications of the addition of 18FDG-Positron Emission Tomography (PET) in CT-based radiotherapy planning for non-small cell lung cancer (NSCLC). Journal of Medical Imaging and Radiation Oncology. 2010;54:152-60.

117. Vinod SK, Lonergan DM. Multisource feedback for radiation oncologists. J Med Imaging RadiatOncol. 2013;57:384-9.

118. Vinod SK, Sidhom M, Gabriel G, Delaney GPP. Factors influencing the use of Guideline-Recommended Therapy in the Management of Lung Cancer. Cancer. 2011;Submitted.

9

119. Vinod SK, Sidhom M, Gabriel G, Lee M, Delaney GPP. Why do some lung cancer patients receive no anti-cancer treatment? Journal of Thoracic Oncology. 2010;5:1-8.

120. Vinod SK, Sidhom MA, Delaney GPP. Do multidisciplinary meetings follow guideline-based care? JOncolPract. 2010;6:276-81.

121. Vinod SK, Sidhom MA, Gabriel GS, Lee MT, Delaney GPP. Why do some lung cancer patients receive no anticancer treatment? JThoracOncol. 2010;5:1025-32.

122. Vinod SK, Simonella L, Goldsbury D, Delaney GPP, Armstrong B, O'Connell DL. Underutilization of radiotherapy for lung cancer in New South Wales, Australia. Cancer. 2010;116:686-94.

123. Vinod SK, Wai E, Alexander C, Tyldesley S, Murray N. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada. J ThoracOncol. 2012;7:1155-63.

124. Walker A, Liney G, Metcalfe P, Holloway L. MRI distortion: considerations for MRI based radiotherapy treatment planning. Australasian Physical & Engineering Sciences in Medicine. 2014;37:103-13.

125. Waller A, Girgis A, Johnson C, Lecathelinais C, Sibbritt D, Forstner D, Liauw W, Currow DC. Improving outcomes for people with progressive cancer: interrupted time series trial of a needs assessment intervention. J Pain Symptom Manage. 2012;43:569-81.

126. Wang D, Koh ES, Descallar J, Pramana A, Vinod SK, Ho Shon I. Application of novel quantitative techniques for FDG-PET/CT in patients with non-small cell lung cancer. Journal of Thoracic Oncology. 2014.

127. Whiting DL, Simpson GK, Koh ES, Wright KM, Simpson T, Firth R. A multi-tiered intervention to address behavioural and cognitive changes after diagnosis of primary brain tumour: a feasibility study. Brain Inj. 2012;26:950-61.

128. Windsor AA, Koh ES, Allen S, Gabriel GS, Yeo AE, Allison R, van der Linden YM, Barton MB. Poor outcomes after whole brain radiotherapy in patients with brain metastases: results from an international multicentre cohort study. ClinOncol(RCollRadiol). 2013;25:674-80.

129. Wong K, Huang SH, O'Sullivan B, Lockwood G, Dale D, Michaelson T, Waldron J, Bayley A, Cummings B, Dawson LA, Kim J, Liu G, Ringash J. Point of care outcome assessment in the cancer clinic: audit of data quality. Radiotherapy and Oncology. 2010;95:339-43.

130. Wright KM, Whiting DL, Simpson GK, Koh ES, Simpson T, Firth R, Gillett L. Development and evaluation of information resources for patients, families and health care providers addressing behavioural and cognitive sequelae of adults with a primary brain tumour. Journal of Neuroscience Nursing. 2014.

131. Xing A, Arumugam S, Deshpande S, Armia G, Holloway L, Goozee G, Gray A, Vial P. Streamlining EPID-based IMRT quality assurance: auto-analysis and auto-report generation. Journal of Physics: Conference Series. 2014;489:012084.

132. Yap M, Vinod S, Delaney GP. Minimally invasive techniques for medically inoperable stage 1 non small cell lung cancer: radiotherapy is still the gold standard. JMedImaging RadiatOncol. 2014;58:134.

133. Yap ML, Vinod SK, Shon IA, Fowler A, Lin M, Gabriel G, Holloway LC. The registration of diagnostic versus planning fluorodeoxyglucose positron emission tomography/computed tomography in radiotherapy planning for non-small cell lung cancer. ClinOncol(RCollRadiol). 2010;22:554-60.

10

134. Young T, Som S, Sathiakumar C, Holloway L. An investigation into positron emission tomography contouring methods across two treatment planning systems. Med Dosim. 2012.

Book Sections

1. Barton M, Delaney GP, Noble D. Radiotherapy: Using risk profiling to Identify Errors and Close Calls. The value of Close Calls in Improving patient Safety: Learning How to Avoid and Mitigate Patient Harm: Joint Commission Resources (JCR) Illinois USA; 2010. p. 103-10.

2. Barton M, Delaney GP, Noble DJ. Radiotherapy: Identifying close calls and errors in the process of care for risk profiling. In: Wu A, editor. The Value of Close Calls in Improving Patient Safety: Learning How to Avoid and Mitigate Harm. Illinois, USA: Joint Commission Resources; 2011. p. 103-10.

3. Barton M, Delaney GP. The optimal provision of cancer treatment services. In: Elwood JM, Sutcliffe S, editors. Cancer Control. Oxford UK: Oxford University Press; 2010. p. 169-84.

4. Barton Mb LM. Glioma of the Central Nervous System Surveillance Counterpoint: Australia 2013. In: F E Johnson, Virgo KS, J. RAA, Thompson F, Maehara Y, Margenthaler JA, et al., editors. Patient Surveillance after Cancer Treatment. New York: Humana Press; 2013. p. 517-9.

5. Barton MB WM, Shafiq RJ. Radiotherapy in the context of cancer control. In: Vienna ERI, editor. Radiotherapy in Cancer Care: facing the global challenge. Vienna, Australia: IAEA; 2013.

6. Barton MB WM. Assessing needs and demand for radiotherapy. In: Vienna ERI, editor. Radiotherapy in Cancer Care: facing the global challenge. Vienna, Australia: IAEA; 2013.

7. Delaney GP, Stebbing J, Thompson AM. Breast Cancer (non metastatic). British Medical Journal Handbook: Clinical Evidence: BMJ Publishing Group; 2010.

8. Delaney GP, Stebbing J, Thompson AM. Clinical Evidence:Breast Cancer (non-metastatic). In: Group BMJP, editor. Clinical Evidence Handbook: BMJ Publishing Group; 2010. p. 607-10.

9. Ghose S, Holloway L, Lim K, Chan P, Veera J, Vinod SK, Liney G, Greer PB, Dowling J. A Survey of Cervix Segmentation Methods in Magnetic Resonance Images. Abdominal Imaging Computation and Clinical Applications: Springer; 2013. p. 290-8.

10. Jacob S, Hovey E, Vinod SK, Delaney GP, Barton M, Ng W. Estimation of an optimal chemotherapy utilisation rate for lung cancer: an evidence-based benchmark for cancer care. 2010.

11. Koh ES, Hanna TP, Barton MB. Current status of Radiotherapy in Australia, New Zealand and Papua, New Guinea. In: Vienna ERI, editor. Radiotherapy in Cancer Care: facing the global challenge. Vienna, Australia: IAEA; 2013.

12. Mackillop WJ, Vinod SK, Lievens Y. The Role of health services research in improving the outcomes for patients with Lung Cancer. In: Pass H, Scagliotti GV, Ball DL, editors. The IASLC Multidisciplinary Approach to Thoracic Oncology 2014. Sydney: IASLC; 2014

11

Grants Chief Investigators Grant Project title Source Year Amount Ebert, Dowling, Denham, Joseph, Gulliford, Dearnaley, Haworth, Holloway, Kron and Greer

Project Grant APP1077788

Radiotherapy treatment for prostate cancer - a change in practice based on direct evidence for targeting and toxicity effects using real outcomes data’

NHMRC 2015-2019 $535,546

Price, W.S.S., J.R. Aldrich-Wright, A. Hennessy, A.S. Sathasivan, A.M. Torres, G.P. Liney, L.C. Holloway, G. Delaney, B.A. Cornell, S.G. Bosi, M. Nyden, B.A. Messerle, C.H. Arns, M.B. Barton, D.J.E. Beves, J.B. Harper, S.R. Meikle, M.R. Bennett, R.M. Bourne, P.J. Keall, M.L. Johns, and E.O. Fridjonsson

Infrastructure grant LE140100009

Ultra-high resolution magnetic resonance imaging (MRI) system for physical applications

Australian Research Council LIEF

2014 $1,064,000

Thwaites, D., L. Holloway, S. Arumugam, S. Vinod, M. Lee, P. Vial, A. Rozenfeld, Y. deDeene, and P. Metcalfe

Project Grant 1067566

Do treatment delivery uncertainties limit the effectiveness of advnaced technology radiotherapy treatments?,

Cancer Council 2014-2017 $359,167

Thwaites, D., L. Holloway, A. Dekker, G. Delaney, M. Bailey, A. Ghose, S. Vinod, A. Miller, and F. Hegi-Johson

Research Project Grant 2014-02

Rapid learning proof-of-concept for NSW radiotherapy: Linking and mining imaging and clinical data to support optimised decisions for NSW lung cancer patients.

NSW Health Office for Health and Medical Research:Bioinformatics collaborative grants program

2014-2015 $250,000

Fahrig, R., P.J. Keall, and L.C. Holloway

R21 grant 1R21EB015957-01

MR-compatible linac gun for robotic linac adaptation

National Institute of Health, USA:R21

2013-2014 $US201,742

12

Holloway, L., G. Delaney, P.E. Metcalfe, P. Vial, and E.S. Koh

Project Grant (1033237),

Quantifying the impact of imaging choice for breast cancer radiotherapy

Cancer Australia and The National Breast Cancer Foundation

2012-2014 $391,596

Keall, P.J., M. Jackson, A. Rozenfeld, M.B. Barton, P.B. Greer, C. Baldock, P.E. Metcalfe, D. Thwaites, Z. Kuncic, S. Bosi, E. Eslick, Vial, P L. Holloway, and S. Downes

Infrastructure Grant (LE120100006)

An adaptable and dedicated linear accelerator for medical radiation research

Australian Research Council:LIEF grant

2012 $600,000

Vial, P., Z. Kuncic, P.B. Greer, C. Baldock, L. Holloway, M.B. Barton, S.A. Meikle, and S.A. Hodgkinson

Project Grant (RG 11-06),

A next generation detector for radiotherapy treatment verification with dual capability for simultaneous imaging and dosimetry

Cancer Council NSW:Research Equipment Grant

2011-2013 $336,125

Vial, P., Z. Kuncic, P.B. Greer, C. Baldock, L. Holloway, M.B. Barton, and S.A. Meikle

Equipment Grant (10/REG/1-20)

Making radiotherapy safer and more accurate: Developing detector technology for the next generation in treatment verification systems

Cancer Institute NSW:Research Equipment Grant

2010-2011

$198,000

Greer, P., Vial, P., Capp, A., Williams, M., Cornes, D., Tang, C., Hatton, J., Keall J

Equipment Grant (10/REG/1-05)

Equipment to assess the accuracy of image-guided and advanced technology used in multi-centre radiotherapy clinical trials

Cancer Institute NSW

2010 – 2011

$94,058

Barton M., Hudson MH., Delaney GP.

NHMRC ID number 510327

Evaluation of radiotherapy re-treatment rates in three major centres

Department of Health and Ageing, via the NHMRC

2010-2012 $503,415

Knight A., Dennis S., Girgis A., Delaney G.

Towards seamless cancer care: what do GPs in South West Sydney need to facilitate better

NSWCI Primary Care Cancer Project Grant

2012-2013 $46,530

13

integration with cancer services?

Girgis A.,Delaney GP., Miller A.,Arnold A.,Carolan M.,Della-Fiorentina S.,Kaadan N.,Avery S.,Van Domburg N.,Ng W.,Spring K

Patient Reported experience collaborative project

Cancer Institute NSW

2013-2015 $200,000

DeSouza P, Barton M, Lee S, Bokey L, Girgis A, Delaney G, Ransom M

13/TRC/1-01

Centre for Oncology Education and Research Translation (CONCERT)

NSW Cancer Institute Translational Cancer Research Centre grants

2014-2018 $6,500,000

Knight A., Delaney G., Liaw S-T., Pennock R., Girgis A.

Fostering integration of general practices with cancer services through improved communication pathways

NSW Cancer Institute Innovation Grant Program Evidence to Practice Grant

2014 $49,990

M Khasraw, K Mcdonald, M Rosenthal, J Simes, E-S Koh et al

VERTU – VEliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma

CURE BRAIN CANCER FOUNDATION

2015-2017 $500,000

M Agar, E Hovey, E-S Koh, J Vardy, K Clark, D Currow, M King, C Brown, K Scott.

Randomised phase II study of acetazolamide plus dexamethasone versus dexamethasone alone for management of cerebral oedema in recurrent or progressive High Grade Glioma.

PERPETUAL

2014-2016 $100,000

J Simes, E-S Koh, M Agar, K McDonald, H Wheeler, A Livingstone

12/CCT/1-

CINSW infrastructure grant COGNO Grant

Cancer Institute NSW

2013-2015 $300,000

E Hovey, E-S Koh, MB Barton, KM Wright, T Simpson, M. Price.

Introduction of a Neuro-oncology Clinical Care Coordinator

Cancer Institute NSW – Health Innovation Grant

2010-2011

$97,000

A Nowak, K Mcdonald, Dr E-S

Australian Genomics and Clinical Outcomes

Cancer Council NSW – Strategic Research

2008-2012 $1,238,114

14

Koh et al of High Grade Glioma Partnership Grant

Keall P, Barton M, Crozier S, Price W

Program Grant APP1036078

The Australian MRI-linac Program: Improving cancer treatment through real time image guided adaptive radiotherapy

NHMRC Program Grant

2013-2017 $5,705,380

Keal P, Barton M, Jackson M, Thwaites D, Kunic Z, Fulton R, Foster K

ACRF Grant

The ACRF Image-X Institute: Eradicating Cancer through Innovation in Imaging and Targeted X-ray Therapy.

Australian Cancer Research Foundation (ACRF)

2014 $1,000,000

M Barton, G Delaney

Review of Radiotherapy Optimal Utilisation Rates

Dept of Health & Ageing, Canberra

2011

15

Clinical Trials

1. TROG 08.03 (RAVES)- Radiotherapy - Adjuvant Versus Early Salvage (RAVES). A Phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with early salvage RT in patients with positive margins or extraprostatic disease following radical prostatectomy

2. TROG 08.06 (STARS)- STARS Breast Trial (STudy of Anastrozole and Radiotherapy Sequencing)

3. TROG 11.03 (P_LUNG)- A Randomised Phase III Trial of High Dose Palliative Radiotherapy (HDPRT) Vs Concurrent Chemotherapy + HDPRT in Patients with Locally Advanced/Small Volume Metastatic Non Small Cell Lung Cancer Not Suitable for Radical Chemo-Radiotherapy

4. ANZUP 1303 (ENZARAD)- A randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer

5. PROMETHEUS- A Phase 2 Multicentre Clinical Trial Exploring a Stereotactic Radiotherapy Boost to the Prostate with Fractionated External Beam Radiotherapy

6. TROG 09.03 (MP3 Study)- A Phase II Efficacy Study of Chemo-radiotherapy in PET Stage II and III Merkel Cell Carcinoma of the Skin

7. TROG 08.08 (TOPGEAR)- A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer

8. TROG 09.02 (CHISEL)- A randomised phase III trial of highly conformal hypofractionated image guided (Stereotactic) radiotherapy (HypoRT) versus conventionally fractionated radiotherapy (ConRT) for inoperable early stage I non-small cell lung cancer

9. TROG 12.01 (HPV Oropharynx)- Weekly Cetuximab/RT Vs Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma

10. GYN MRI- Developing methods to allow adaptive radiotherapy for gynaecological cancers with MRI

11. TROG 08.04 (PORTEC)- Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma

12. TROG 03.04 (RADAR)- A randomised trial investigating the effect of biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate

13. TROG 03.06 (TOAD)- A collaborative randomised phase III trial: The timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA

14. TROG 07.01 (DCIS)- A randomised phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast

15. STARS Pilot- Pilot for a randomised comparison of Anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy

16. EORTC 22033-26033 (LGG)- Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas (LGG) after stratification for genetic 1p loss: a phase III study

17. TROG 05.01 (POST)- Post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck

18. TROG 03.05 (MA20)- A phase III study of regional radiation therapy in early breast cancer 19. BIG 2-04 (SUPREMO)- A phase III randomised trial to assess the role of adjuvant chest wall

irradiation in ‘intermediate risk’ operable breast cancer following mastectomy (Selective Use of Postoperative Radiotherapy AftEr MastectOmy)

20. TROG 11.A (ANROTAT)- The assessment of new radiation oncology technologies and treatments

21. TROG 04.02 (Cervical)- Prospective study to determine the relationships between survival and FIGO stage, tumour volume and corpus invasion in cervical cancer

16

22. TROG 03.02 (Gastric)- A feasibility study to evaluate adjuvant chemo-radiotherapy for gastric cancer

23. TROG 01.04 (Rectum)- A randomised trial of preoperative radiotherapy for stage T3 adenocarcinoma of rectum

17

Invited presentations

Speaker/s Topic Meeting Year 1. Barton MB Radiotherapy demand and

benefits UICC World Cancer Congress, Melbourne

2014

2. Barton MB Adapting radiotherapy utilisation rates to different countries

International Atomic Energy Agency, Vienna, Austria

2014

3. Barton MB Estimating the demand for radiotherapy

University Hospital Ghent, Belgium

2014

4. Barton MB The Australian MRI LINAC program Princess Margaret Hospital, Toronto, Canada

2014

5. Barton MB Keynote address Research Futures Forum, University of Western Sydney

2013

6. Barton MB The Australian MRI LINAC project Cambridge UK 2012 7. Barton MB Is VUCCnet reproducible? UICC ASM, Montreal

Canada 2012

8. Barton MB Comparative ethics Law Society NSW. Sydney, Australia

2012

9. Barton MB Burnie versus Darwin: a tale of two cities

4th National Cancer Centres Symposium. Melbourne, Australia.

2012

10. Barton MB Core competencies: are they applicable in developing countries?

IAEA workshop. Vienna, Austria

2012

11. Barton MB The cancer workforce in Australia Plenary, Clinical Oncology Society of Australia, Perth.

2011

12. Barton MB Access to cancer services and education in Low and Middle Income Countries

World Congress on Lung Cancer, Amsterdam, the Netherlands.

2011

13. Barton MB Optimum utilisation of cancer services

RADAIM, Sydney, NSW 2011

14. Barton MB Review of Cancer Services in WA Cancer Summit, Forum to Develop a WA State Cancer Plan, Perth

2010

15. Barton MB Existing training programmes and key institutions in Africa to serve VUCCnet

Virtual University for Cancer Control Network in Africa First Planning Meeting, Ghana

2010

16. Delaney GP The role of MRI in Radiation Oncology

Royal North Shore Hospital, Sydney

2014

17. Delaney GP A Multi-patient incident RANZCR Combined Scientific Meeting, Melbourne

2014

18. Delaney GP Minimising the impact of incidents in Radiotherapy

RANZCR Combined Scientific Meeting, Melbourne

2014

19. Delaney GP The current trends in breast cancer research

University of Beijing Cancer Hospital, Beijing, China

2014

18

20. Delaney GP The role of MRI in Radiation Oncology

RANZCR Combined Scientific Meeting, Melbourne

2014

21. Delaney GP The role of imaging in the developments of Radiation Oncology

Liverpool Hospital Grand Rounds

2014

22. Delaney GP Minimising the impact of incidents in radiotherapy

ROSIS Conference Dublin, Ireland

2013

23. Delaney GP Update on radiotherapy in Early Breast Cancer

International Breast Cancer Symposium, Sydney, Australia

2012

24. Delaney GP Detecting Error and Clinical Consequences: Acute & chronic complications of accidents. How can accidents be clinically detected?

Patient Safety in Radiation Oncology Workshop ROSIS Australian Organising Committee, Melbourne, Australia

2012

25. Delaney GP Update on Cancer Services in South Western Local Health District

South Western Sydney Public Forum SWSLHD, Liverpool, Australia

2012

26. Delaney GP Oncological Emergencies Grand Rounds Fairfield Hospital

2011

27. Delaney GP Multi-disciplinary Management of Breast Cancer

Information Evening Liverpool Division of General Practice Meeting

2011

28. Forstner D Particle Therapy Western Sydney LHD 2014 29. Forstner D Inquiry into skin cancer in

Australia Presentation to Parliament of Australia House of Representatives Standing Committee on Health

2014

30. Forstner D Management of Head & Neck Cancer

NSW Oncology Pharmacists 2014

31. Forstner D Advanced Radiation therapy RANZCR FRO Summit, Canberra

2014

32. Forstner D Better Radiotherapy RANZCR FRO Summit, Canberra

2012

33. Holloway L The art and science of lesion contouring on PET/CT: Looking back towards tomorrow

Functional Imaging in radiation oncology, Sydney

2015

34. Holloway L An overview of research at Liverpool

Peter MacCallum Cancer Institute, Melbourne

2014

35. Holloway L Uncertainties in delineation of radiotherapy target volumes: influences and impact

Combined Scientific Meeting, Melbourne

2014

36. Holloway L The Australian MRI-linac program University of Michigan, Ann Arbor, Michigan.

2014

37. Holloway L MRI-guided radiotherapy technologies

University of Michigan, Ann Arbor, Michigan.

2014

38. Holloway L Uncertainties in radiotherapy Maastro Clinic, Maastricht, The Netherlands

2014

39. Holloway L The Australian MRI-linac program Maastro Clinic, Maastricht, 2014

19

The Netherlands 40. Holloway L Uncertainties in radiotherapy

delineations Stanford University, Palo Alto, CA, USA

2013

41. Holloway L A proposal for an in-line MRI linac at Liverpool hospital

ACPSEM QLD Branch Symposium, Brisbane

2010

42. Koh ES The impact of neuro-oncology care coordination

Brain Tumour Clinical Education Day: Cancer Council Queensland

2013

43. Koh ES Overview of Radiotherapy in CNS tumours

Neurosurgical Nursing Professional Development Scholarship Committee (NNPDSC) Conference, Sydney

2012

44. Koh ES Late treatment effects on Neurocognition

Cooperative Trials Group for Neuro-Oncology (COGNO) – 5th ASM, Brisbane

2012

45. Lee M SBRT: Introduction, history, principle

Liver stereotactic ablative radiotherapy workshop, Seoul, Korea

2013

46. Lee M Introduction to Liver SBRT: current approach, outcome, efficacy

Liver stereotactic ablative radiotherapy workshop, Seoul, Korea

2013

47. Lee M Steps in setting up a Liver SBRT program: pre-RT evaluation, dose fractionation, prescription

Liver stereotactic ablative radiotherapy workshop, Seoul, Korea

2013

48. Lee M Liver SBRT: Take home message, current trials and future directions

Liver stereotactic ablative radiotherapy workshop, Seoul, Korea

2013

49. Lee M Liver stereotactic ablative radiotherapy

RANZCR ASM, Auckland, New Zealand

2013

50. Lee M The role of radiotherapy for stage IV rectal cancer

CSSANZ Spring Meeting 2012

51. Lim K Imaging in the Management of Cervix Cancer – the Good, the Bad & the Ugly

The Royal Australian and New Zealand College of Radiologists 64th ASM

2013

52. Lim K Radiation Oncology Contouring Workshop

Australia New Zealand Gynaeocological Oncology Group ASM, Gold Coast

2013

53. Lim K Adaptive Radiotherapy for Cervix Cancer

12th Interdisciplinary Radiation Oncology Seminar: Adapt to the Future, Sydney

2011

54. Lim K Target Volumes, Organ motion and Contouring Pitfalls in IMRT

13th Biennial Meeting of the International Gynecologic Cancer Society, Prague, Czech Republic

2010

55. Lim K Feasibility, Concerns and methods for Target Coverage and OAR

American Brachytherapy Society Annual meeting,

2010

20

Sparing when using IMRT/ IGRT for Cervix cancer: Consensus Guidelines on Contouring

Atlanta, GA.

56. Liney G Physics of MRI Siemens ANZ Research Users Meeting, Sunshine Coast, Queensland

2014

57. Liney G MRI for radiation treatment planning

TROG, Sunshine Coast, Queensland

2014

58. Liney G Physics of MRI TROG, Sunshine Coast, Queensland

2014

59. Liney G MRI in Radiotherapy EPSM, Perth, Australia 2013 60. Liney G MRI for radiation treatment

planning Siemens User meeting, Sydney

2013

61. Liney G MRI for radiation treatment planning

SFPM-EFOMP Congress, Strasbourg, France

2012

62. Liney G Image Quality Leeds Test Objects Meeting, Leeds, UK

2012

63. Liney G MRI Safety Bayer Scientific, Leeds, UK 2011 64. Vial P The Impact of neuro-oncology

care coordination Brain Tumour Clinical Education Day, Cancer Council, Queensland

2013

65. Vial P EPID detectors EPI2k14, International conference on Electronic Patient Imaging, Aarhus, Denmark

2014

66. Vial P Treatment Planning: Patient Specific QA

Training Course on the Physics of External Photon Beam Radiation Treatment Planning (University of Sydney)

2013

67. Vial P Treatment Delivery: Patient Specific QA

Training Course on the Physics of External Photon Beam Radiation Treatment Planning (University of Sydney)

2013

68. Vial P Set-up Studies in Radiation Therapy

EPSM summer school, Melbourne – Image Guided Radiation Therapy (IGRT)

2010

69. Vinod SK In vivo dosimetry for IMRT 16th International Conference on Solid State Dosimetry - Summer School (Wollongong)

2010

70. Vinod SK Gynaecological Brachytherapy. Lecture and examiner

Clinical Brachytherapy Workshop organised by Australasian Brachytherapy Group. Melbourne

2013

71. Vinod SK Multidisciplinary Decisions in Lung Cancer

Modelling Demand for Radiotherapy Workshop, Health Economics in Radiation Oncology,

2013

21

ESTRO. Geneva, Switzerland

72. Vinod SK Do Multidisciplinary Team Meetings improve outcomes in lung cancer?

ALCC, Melbourne 2010

73. Vinod SK Radiation Oncology & Nuclear Medicine: A Marriage Made in Heaven or Trouble in Paradise?

ANZ Society of Nuclear Medicine

2010

22

Awards

1. Batumalai V- John A Koveleski Award for Professional Development (SMRT-2015) 2. Thwaites D, Holloway L, Dekker A, Delaney G, Bailey M, Ghose A, Vinod S, Miller A, Hegi-

Johnson F- Best submitted abstract ( Cancer Institute Innovations conference 2014) 3. Barton MB- Rouse Travelling Fellowship (RANZCR-2014) 4. Dundas K, Pogson E, Batumalai V, Vial P, Boxer M, Yap ML, Koh ES, Delaney G, Metcalfe P,

and Holloway L- best presentation award (radiation therapists research meeting 2014) 5. Delaney GP- Australia Day Award for Health Research (Liverpool Council- 2014) 6. Delaney GP- Outstanding Service or Achievement Award (NSW Premier’s Department- 2014) 7. Gabriel G- One of 20 for the ESTRO Best Poster Award (ESTRO-2013) 8. Barber J, Yau S, White S, Sykes J, Arumumgam S, Holloway L, and Thwaites D- Varian Prize

for best radiotherapy presentation (EPSM 2013) 9. Kaadan N, Farrugia S, Sharmin S, Vinod S, Descallar J- Best Poster (Cancer Institute NSW-

2014) 10. Yap ML, Delaney GP, Shafiq J, Jacob S, Wong K, Thompson S, Hanna T, Barton M- Chris

Atkinson Award for best scientific presentation in radiation oncology-(Combined Scientific Meeting- 2014)

11. Barton MB- Novartis Oncology Cancer Achievement Award (Medical Oncology Group of Australia- 2012)

12. Dimigen M, Vinod S, Tran T, Lim K- Innovations in Cancer Treatment Award (Cancer Institute NSW- 2012)

13. Duggan K, Vinod S, Descallar J -Best of the best poster presentation (COSA ASM-2012) 14. Kelly J, Vinod S, Shafiq- Best of the best poster presentation (COSA ASM- 2012) 15. Radiation Oncology Department- Liverpool Hospital General Manager’s Innovation Award

(Liverpool Hospital- 2012) 16. Jameson M, Bailey M, Foo K, Holloway L, Metcalfe P- Postgraduate prize (ACPSEM-2011) 17. Veera J- Best Exhibit Award (RANZCR- 2011) 18. Wong K, Barton MB, Delaney GP- Best Radiation Oncology Scientific Paper Presentation

(RANZCR-2011) 19. Boxer M, Vinod S, Shafiq J, Duggan K- Paper of the year (Liverpool Hospital- 2012)

23

Proposed Budget

This is based on the stated grant of $100,000 per annum. This amount needs to include oncosts (20%) and then annual salary increases (likely to be approximately 3%). Therefore the initial starting salary will need to be capped at $79,000 per annum to allow for the annual increases and oncosts.

• Would be responsible to the Chair of the Radiation Oncology Research Executive and the Director of Radiation Oncology.

• We would be open to a part-time applicant with well developed research coordination skills.

• There are approved clinical trials positions in radiation oncology for appointment under the Health Services Manager classification, nursing and radiation therapy classifications. We would aim to use one of these to avoid the delays and administrative challenges associated with developing a new job and getting it through the existing grading systems. Ideally given the content knowledge associated with this position we would propose appointing under the Radiation Therapy classification and an example position description (at Grade 3 Level 2) is attached.

• The aim would be to appoint in July 2015 when the funding becomes available.

• Work closely with all members of the Research Executive and the Radiation Oncology Clinical Trials Unit

• Support research Executive and the key research staff to support the department’s research activities across all areas of research not just to a single project. This position would not providing secretarial support – that would continued to be provided from within current budget.

• Liaise with SWSLHD HREC office • Manage new research proposal and over see governance • Look for further funding opportunities • Look for strategic opportunities • Support opportunities to generate income from existing resources – such

as MRI simulator. • We would need to take advice from SWSLHD whether the position would

needed to be appointed through a SWSLHD facility or whether it could be appointed through the Ingham Institute where at least one of our clinical trials manager is appointed along with a number of our research staff. We foresee significant advantages to appointing through the Ingham Institute.

POSITION DESCRIPTION

Reference Number : 176854 Recruitment Type General Recruitment Position Number : Position Title : Level 3 Grade 2 Research Radiation Therapist (Research coordinator) Cost Centre :

Cost Centre Code % xxx

xxxxx

100

Organisation unit : South Western Sydney Local Health District

Location : Liverpool Facility : Liverpool Hospital Award Classification :

Health Employees' Medical Radiation Scientists (State) Award-Radiation Therapist Lvl 3 Gde 2

Registration/ Licence Requirements :

Medical Radiation Practitioner

Vaccination Category :

A

Employment Screening Check National Criminal Record Check :

Yes

Working With Children Background Check :

No

Working With Aged Care Check :

No

Responsible To : Jointly the Director of Radiation Oncology, Director of Radiation Therapy, Chair Radiation Oncology Research Executive

Responsible For : Level 1 Radiation Therapists & RT students, also for coordinating all Radiation Oncology research

Purpose Of Position :

The Research Radiation Therapist will co-ordinate and undertake research projects within the Radiation Therapy team across the Liverpool and Macarthur Cancer Therapy Centres, including all work associated with Radiation Oncology Research Executive, assisting with developing Radiation Therapist led research, mentoring staff undertaking research, participating in multi-disciplinary projects and the development of first class service patient care.

Key Accountabilities :

The scope of practice of the accredited Research Radiation Therapist shall include: • It is anticipated that the equivalent of 9 days per fortnight will be spent in this research and development role with the focus on undertaking specific research projects and meeting the objectives of the Radiation Oncology Research Plan 2011. • Taking the coordination lead within the Radiation Oncology Research Executive, including managing existing projects which may include the introduction & development of equipment, techniques and practice in coordination with the strategic research directions of the radiation oncology research at Liverpool and Campbelltown. • Represent Radiation Therapy on the the research executive committee • Demonstration of flexibility and adaptability in order to facilitate projects which may have to occur at unusual times, as well as at both Radiotherapy centres within SWSCS (Liverpool and Macarthur). • Investigate and advertise national and international research opportunities to staff in an appropriate manner • This position is accountable to the Radiation Oncology Research Committee. • Be a role model to all staff and students in their commitment to Continuing Professional Development activities • Assist where applicable with multi- disciplinary team training and education • To promote a positive and harmonious work environment and maintain open communication channels • Maintenance of professional currency • To be actively involved in ensuring all treatment deviations are investigated, reported and

Challenges/Problem Solving :

Communication :

Decision Making :

Selection Criteria :

corrective measures implemented where appropriate. • To participate in the recruitment of new staff. To be aware of and current with all departmental procedures in relation to:- • Patient positioning and immobilisation, • Manufacture/construction of ancillary equipment, • Simulation, including tumour localisation, treatment planning and dosimetry, • Treatment delivery with superficial to megavoltage external beams and verification, • Imaging for planning and treatment verification purposes, • Maintain appropriate departmental and patient records. • Patient assessment including psychosocial issues, at all times ensuring the confidentiality of patient information and recognising the need for patient privacy. • To develop, maintain & abide by departmental protocols including Quality Assurance procedures • Working as part of the health delivery team. • Maintenance of a clean and orderly environment • Compliance with infection control policies of the hospital. • Carrying out such responsibilities consistent with the relevant award, level of experience or terms of employment as may be directed or implied from time to time. • To be available for flexible work hours and locations across the LHD as required by the demands of the Service

• To assist with the development of ongoing research initiatives for all levels of staff and to design appropriate training for new technologies which is relevant to all levels of career experience and all learning styles in conjunction with the RT Educators • Responsibility for the provision and facilitation of research and development within the radiation therapy team, ensuring that departmental practices are current & aligned with international best practice standards. • To maintain clinical skills and stay up to date with technological developments in radiotherapy in order to train towards new initiatives in a proactive manner • To implement quality and research activities which guide service delivery and continued improvement • To ensure timely and accurate data collection for all patients enrolled in Radiation Oncology clinical trials • To provide a caring and understanding environment for the patient and carers.

• Attend and give regular education sessions, attend research and Trial specific meetings within the CTC as required, as well as attending RT specific meetings and training with Radiotherapy Educator. • To ensure adequate response in research initiatives to any SWSLHD or NSW Health protocol changes • To maintain effective communication with other Radiation Therapy Researchers throughout NSW and Australasia, in order to promote research and development and ensure local initiatives are in keeping with the wider professional community • Attendance at Research Executive meetings • Attendance at staff, senior, patient review, and any other department meetings as deemed appropriate to their role by the Director of Radiation Therapy. • Liaison with Radiation Oncologists, Medical Physicists, Nurses and other members of the Oncology Multi-Disciplinary team, particularly relating to research input from these groups • Demonstrated ability to communicate with other LHD personnel •Review departmental systems and documentation to monitor adherence to protocols, level of accuracy and efficiency, especially in regards to research trials, new patient techniques and new technology •Endure departmental quality control is maintained in regards to all patient activities •Decisions pertinent to trial design, research topics and development projects and those relating to patients within clinical trials in conjunction with the relevant Radiation oncologist. • Decisions relating to the education of Radiation Therapy teams are made both independently and also in consultation with the Radiation Therapy Management Group

Selection Criteria Experience with high energy linear accelerators with electron capabilities and multileaf collimation (MLC), and experience with electronic verification imaging, and experience with 3D treatment planning systems with CT interface. Demonstrated effective organisational and time management skills including an ability to self-motivate and self-direct own training & learning, including personal ongoing continuing professional development. Successful completion of a degree in Medical Radiation Technology or equivalent qualification recognised by the Australian Institute of Radiography & holder of a validated Statement of Accreditation. Eligible for licensing / registration by the State's regulatory authority. Demonstrated capacity to supervise, educate, train and objectively assess Radiation Therapists, NPDP's and student RT's in current & new practice and technologies and provide advice to remedy deficiencies in knowledge and skills. Evidence of active participation/involvement in research and development through associated presentations, conferences, publications; or workplace in-services. Completion of or intention to undertake postgraduate study in Radiation Therapy or a relevant field with an appropriate research component. Can demonstrate knowledge of the principles & practices of research participation and clinical trials procedures as well as a high level of understanding of Radiation Therapy QA, QI and radiation safety principles and practices.

Can demonstrate effective communication and interpersonal skills, both spoken and written including the ability to clearly communicate complex issues to all levels of staff.

Staffing : Nil Budget : Nil Financial Delegation: Nil

JOB DEMANDS CHECKLIST Physical Demands Frequency Sitting - remaining in a seated position to perform tasks Frequent Standing - remaining standing without moving about to perform tasks Frequent Walking - Floor type: even / uneven / slippery, indoors / outdoors, slopes Occasional Running - Floor type: even / uneven / slippery, indoors / outdoors, slopes Not Applicable Bend/Lean Forward from Waist - Forward bending from the waist to perform tasks Frequent Trunk Twisting - Turning from the waist while sitting or standing to perform tasks Frequent Kneeling - remaining in a kneeling posture to perform tasks Not Applicable Squatting / Crouching - Adopting a squatting or crouching posture to perform tasks Infrequent Leg / Foot Movement - Use of leg and / or foot to operate machinery Occasional Climbing (stairs/ladders) - Ascend / descend stairs, ladders, steps Occasional Lifting / Carrying - Light lifting & carrying: 0 - 9 kg Occasional Lifting / Carrying - Moderate lifting & carrying: 10 - 15 kg Infrequent Lifting / Carrying - Heavy lifting & carrying: 16kg & above Not Applicable Reaching - Arms fully extended forward or raised above shoulder Infrequent Pushing / Pulling / Restraining - Using force to hold / restrain or move objects toward or away from the body Infrequent

Head / Neck Postures - Holding head in a position other than neutral (facing forward) Occasional Hand & Arm Movements - Repetitive movements of hands and arms Frequent Grasping / Fine Manipulation - Gripping, holding, clasping with fingers or hands Constant Work At Heights - Using ladders, footstools, scaffolding, or other objects to perform work Infrequent

Driving - Operating any motor powered vehicle Not Applicable Sensory Demands Frequency Sight - Use of sight is an integral part of work performance e.g. Viewing of X-Rays, computer screens Constant

Hearing - Use of hearing is an integral part of work performance e.g. Telephone enquiries Constant

Smell - Use of smell is an integral part of work performance e.g. Working with chemicals Occasional Taste - Use of taste is an integral part of work performance e.g. Food preparation Not Applicable Touch - Use of touch is an integral part of work performance Constant Psychosocial Demands Frequency Distressed People - e.g. Emergency or grief situations Constant Aggressive & Uncooperative People - e.g. drug / alcohol, dementia, mental illness Infrequent Unpredictable People - e.g. Dementia, mental illness, head injuries Occasional Restraining - involvement in physical containment of patients / clients Not Applicable Exposure to Distressing Situations - e.g. Child abuse, viewing dead / mutilated bodies Frequent

Environmental Demands Frequency Dust - Exposure to atmospheric dust Not Applicable Gases - Working with explosive or flammable gases requiring precautionary measures Not Applicable Fumes - Exposure to noxious or toxic fumes Not Applicable Liquids - Working with corrosive, toxic or poisonous liquids or chemicals requiring PPE Infrequent Hazardous substances - e.g. Dry chemicals, glues Infrequent Noise - Environmental / background noise necessitates people raise their voice to be heard Infrequent

Inadequate Lighting - Risk of trips, falls or eyestrain Not Applicable Sunlight - Risk of sunburn exists from spending more than 10 minutes per day in sunlight Not Applicable

Extreme Temperatures - Environmental temperatures are less than 15C or more than 35C Not Applicable

Confined Spaces - areas where only one egress (escape route) exists Not Applicable Slippery or Uneven Surfaces - Greasy or wet floor surfaces, ramps, uneven ground Not Applicable

Inadequate Housekeeping - Obstructions to walkways and work areas cause trips and falls

Infrequent

Working At Heights - Ladders / stepladders / scaffolding are required to perform tasks Not Applicable Biological Hazards - e.g. exposure to body fluids, bacteria, infectious diseases Infrequent

As the incumbent of this position, I confirm I have read the Position Description and Job Demands Checklist, understand its content and agree to work in accordance with the requirements of the position.

Employee Name:

Employee Signature Date:

Manager's Name:

Manager's Signature Date: